const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  HeadingLevel, AlignmentType, BorderStyle, WidthType, VerticalAlign,
  PageNumber, PageBreak, LevelFormat, Header, Footer, ExternalHyperlink
} = require('docx');
const fs = require('fs');

// ── Helpers ──────────────────────────────────────────────────────────────────
const plain = (text, opts = {}) =>
  new Paragraph({ children: [new TextRun({ text, ...opts })] });

const heading1 = (text) =>
  new Paragraph({ heading: HeadingLevel.HEADING_1, children: [new TextRun({ text, bold: true })] });

const heading2 = (text) =>
  new Paragraph({ heading: HeadingLevel.HEADING_2, children: [new TextRun({ text, bold: true })] });

const heading3 = (text) =>
  new Paragraph({ heading: HeadingLevel.HEADING_3, children: [new TextRun({ text, bold: true, italics: true })] });

const body = (text) =>
  new Paragraph({
    children: [new TextRun({ text, font: 'Arial', size: 24 })],
    spacing: { after: 160 }
  });

const italic = (text) =>
  new Paragraph({
    children: [new TextRun({ text, font: 'Arial', size: 24, italics: true })],
    spacing: { after: 160 }
  });

const spacer = () => new Paragraph({ children: [new TextRun('')], spacing: { after: 120 } });

const cite = (num) => new TextRun({ text: `[${num}]`, font: 'Arial', size: 18, superScript: true });

const bodyWithCites = (text, refs) =>
  new Paragraph({
    children: [
      new TextRun({ text, font: 'Arial', size: 24 }),
      ...refs.map(r => cite(r))
    ],
    spacing: { after: 160 }
  });

// ── Reference list helper ─────────────────────────────────────────────────────
const refEntry = (num, text) =>
  new Paragraph({
    children: [new TextRun({ text: `${num}. ${text}`, font: 'Arial', size: 22 })],
    spacing: { after: 120 }
  });

// ── Table helper ──────────────────────────────────────────────────────────────
const tableCell = (text, shade = false) =>
  new TableCell({
    shading: shade ? { fill: 'D9E2F3', type: 'clear' } : undefined,
    children: [new Paragraph({ children: [new TextRun({ text, font: 'Arial', size: 20, bold: shade })] })],
    verticalAlign: VerticalAlign.CENTER
  });

const buildTable = (headers, rows) =>
  new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [
      new TableRow({
        children: headers.map(h => tableCell(h, true))
      }),
      ...rows.map(row =>
        new TableRow({ children: row.map(cell => tableCell(cell)) })
      )
    ]
  });

// ── Document content ──────────────────────────────────────────────────────────
const doc = new Document({
  styles: {
    default: {
      document: { run: { font: 'Arial', size: 24 } }
    },
    paragraphStyles: [
      {
        id: 'Heading1', name: 'Heading 1', basedOn: 'Normal', next: 'Normal', quickFormat: true,
        run: { size: 36, bold: true, font: 'Arial', color: '1F3864' },
        paragraph: { spacing: { before: 360, after: 240 }, outlineLevel: 0 }
      },
      {
        id: 'Heading2', name: 'Heading 2', basedOn: 'Normal', next: 'Normal', quickFormat: true,
        run: { size: 28, bold: true, font: 'Arial', color: '2E5496' },
        paragraph: { spacing: { before: 280, after: 160 }, outlineLevel: 1 }
      },
      {
        id: 'Heading3', name: 'Heading 3', basedOn: 'Normal', next: 'Normal', quickFormat: true,
        run: { size: 24, bold: true, italics: true, font: 'Arial', color: '2E5496' },
        paragraph: { spacing: { before: 200, after: 120 }, outlineLevel: 2 }
      }
    ]
  },
  sections: [{
    properties: {
      page: {
        size: { width: 12240, height: 15840 },
        margin: { top: 1440, right: 1440, bottom: 1440, left: 1440 }
      }
    },
    headers: {
      default: new Header({
        children: [new Paragraph({
          alignment: AlignmentType.RIGHT,
          children: [new TextRun({ text: 'Narrative Review | Fluoroquinolone Resistance', font: 'Arial', size: 18, color: '666666' })]
        })]
      })
    },
    footers: {
      default: new Footer({
        children: [new Paragraph({
          alignment: AlignmentType.CENTER,
          children: [
            new TextRun({ text: 'Page ', font: 'Arial', size: 18, color: '666666' }),
            new TextRun({ children: [PageNumber.CURRENT], font: 'Arial', size: 18, color: '666666' }),
            new TextRun({ text: ' of ', font: 'Arial', size: 18, color: '666666' }),
            new TextRun({ children: [PageNumber.TOTAL_PAGES], font: 'Arial', size: 18, color: '666666' })
          ]
        })]
      })
    },
    children: [

      // ── TITLE BLOCK ──
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: 480, after: 240 },
        children: [new TextRun({
          text: 'Beyond First-Line Defence: Addressing Fluoroquinolone Resistance Through Mechanistic Insight, Stewardship and Innovation',
          bold: true, font: 'Arial', size: 40, color: '1F3864'
        })]
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { after: 120 },
        children: [new TextRun({
          text: 'A Narrative Review',
          font: 'Arial', size: 24, italics: true, color: '444444'
        })]
      }),
      spacer(),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { after: 80 },
        children: [new TextRun({ text: 'Corresponding Author: [Author Name, Credentials]', font: 'Arial', size: 22, color: '555555' })]
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { after: 80 },
        children: [new TextRun({ text: 'Affiliation: [Department, Institution, City, Country]', font: 'Arial', size: 22, color: '555555' })]
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { after: 80 },
        children: [new TextRun({ text: 'Email: [corresponding.author@institution.edu]', font: 'Arial', size: 22, color: '555555' })]
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { after: 80 },
        children: [new TextRun({ text: 'Running title: Fluoroquinolone Resistance: Mechanisms, Stewardship and Innovation', font: 'Arial', size: 22, italics: true, color: '555555' })]
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { after: 80 },
        children: [new TextRun({ text: 'Word count: ~7,200 | Tables: 2 | Date: July 2026', font: 'Arial', size: 22, color: '555555' })]
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { after: 80 },
        children: [new TextRun({ text: 'Keywords: fluoroquinolones; antimicrobial resistance; DNA gyrase; antimicrobial stewardship; gepotidacin; zoliflodacin; plasmid-mediated resistance', font: 'Arial', size: 22, italics: true, color: '555555' })]
      }),

      // ── ABSTRACT ──
      new Paragraph({ children: [new PageBreak()] }),
      heading1('Abstract'),
      new Paragraph({
        children: [new TextRun({ text: 'Background: ', bold: true, font: 'Arial', size: 24 }),
          new TextRun({ text: 'Fluoroquinolones (FQs) have been cornerstones of empirical therapy for decades, offering broad-spectrum activity and favourable oral bioavailability. However, escalating resistance rates now threaten their clinical utility across a wide range of gram-negative and gram-positive pathogens. Ciprofloxacin resistance in Escherichia coli isolated from urinary tract infections approaches 40% in many geographic regions, and multidrug-resistant Neisseria gonorrhoeae has rendered FQs largely obsolete for gonorrhoea.', font: 'Arial', size: 24 })],
        spacing: { after: 160 }
      }),
      new Paragraph({
        children: [new TextRun({ text: 'Objectives: ', bold: true, font: 'Arial', size: 24 }),
          new TextRun({ text: 'This narrative review synthesises current knowledge on the pharmacological mechanisms of FQs, the molecular and epidemiological dimensions of resistance, the adverse-event profile that constrains prescribing, and evidence-based stewardship strategies. It further evaluates the pipeline of next-generation topoisomerase inhibitors and complementary therapeutic innovations.', font: 'Arial', size: 24 })],
        spacing: { after: 160 }
      }),
      new Paragraph({
        children: [new TextRun({ text: 'Methods: ', bold: true, font: 'Arial', size: 24 }),
          new TextRun({ text: 'A narrative review of peer-reviewed literature was performed using PubMed, MEDLINE, and web-based surveillance databases from 2015 to July 2026. Studies were selected on the basis of relevance to resistance mechanisms, stewardship outcomes, and emerging therapeutics.', font: 'Arial', size: 24 })],
        spacing: { after: 160 }
      }),
      new Paragraph({
        children: [new TextRun({ text: 'Results: ', bold: true, font: 'Arial', size: 24 }),
          new TextRun({ text: 'Three primary resistance mechanisms have been characterised: target-site mutations in quinolone resistance-determining regions (QRDRs) of gyrA/gyrB and parC/parE; plasmid-mediated quinolone resistance (PMQR) genes including qnr variants, aac(6\')-Ib-cr, and efflux gene operons; and upregulation of chromosomal efflux pumps (AcrAB-TolC, MexAB-OprM). Global surveillance data demonstrate that FQ resistance in E. coli causing urinary tract infections reaches a pooled prevalence of approximately 39-40%, with marked regional variation. Antimicrobial stewardship programmes incorporating FQ restriction policies, clinical decision support tools, and local antibiogram guidance have demonstrated measurable reductions in resistant isolate rates. Gepotidacin and zoliflodacin, novel bacterial topoisomerase inhibitors unaffected by classical QRDR mutations, have shown promising efficacy in phase 3 trials for gonorrhoea and are pending regulatory approval. Phage therapy, anti-biofilm agents, and artificial intelligence-assisted drug discovery represent emerging complementary strategies.', font: 'Arial', size: 24 })],
        spacing: { after: 160 }
      }),
      new Paragraph({
        children: [new TextRun({ text: 'Conclusions: ', bold: true, font: 'Arial', size: 24 }),
          new TextRun({ text: 'Addressing FQ resistance demands a tripartite response: rigorous mechanistic understanding to identify new drug targets, disciplined stewardship to preserve residual efficacy, and accelerated investment in next-generation topoisomerase inhibitors and non-antibiotic modalities. Clinicians, microbiologists, pharmacists, and public health authorities must act in concert to extend the useful lifespan of this antimicrobial class.', font: 'Arial', size: 24 })],
        spacing: { after: 160 }
      }),

      // ── 1. INTRODUCTION ──
      new Paragraph({ children: [new PageBreak()] }),
      heading1('1. Introduction'),
      body('Fluoroquinolones (FQs) represent one of the most transformative antibiotic classes developed in the latter half of the twentieth century. First introduced clinically in the 1960s with nalidixic acid and subsequently expanded through successive generations of fluorinated derivatives, FQs now include agents such as ciprofloxacin, levofloxacin, moxifloxacin, and ofloxacin. Their appeal lies in a combination of potent bactericidal activity, excellent oral bioavailability approaching 70-100% for most members, broad tissue penetration including into the prostate and central nervous system, and a spectrum covering gram-negative enteric organisms, atypical respiratory pathogens, and, for the respiratory fluoroquinolones, gram-positive cocci.'),
      bodyWithCites('For these reasons, FQs became first- or second-line agents for urinary tract infections (UTIs), community-acquired pneumonia, infectious diarrhoea, sexually transmitted infections including gonorrhoea, prostatitis, and prophylaxis in immunocompromised hosts. Their clinical versatility was matched by their commercial success, and by the early 2000s FQs ranked among the most prescribed antibiotics globally.', [1]),
      body('Yet the very properties that made FQs so clinically attractive - broad-spectrum activity, ready oral availability, and ease of prescribing - also accelerated resistance selection. The World Health Organization (WHO) 2025 Global Antibiotic Resistance Surveillance Report documented ciprofloxacin resistance among E. coli isolates from urinary tract infections at approximately 39.8% by pooled systematic review estimates, nearly matching rates identified in the WHO GLASS surveillance network. Resistance in Salmonella spp. reached 38.1% for ciprofloxacin in the same analyses - a figure that carries profound implications for the management of enteric fever in resource-limited settings.'),
      bodyWithCites('In parallel, the adverse-event profile of FQs has attracted increasing regulatory attention. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued successive black-box warnings regarding FQ-associated tendinopathy, tendon rupture, peripheral neuropathy, and aortic aneurysm. The FDA further restricted FQ use for uncomplicated UTIs and acute sinusitis in 2016, citing a risk-benefit profile that no longer supported routine first-line use. These restrictions have reinforced stewardship messaging that FQs should be reserved for conditions where no safe alternative exists.', [2]),
      body('This narrative review addresses fluoroquinolone resistance from three integrated perspectives: the mechanistic biology that drives and sustains resistance; the epidemiological burden and clinical consequences; and the stewardship and innovation strategies that constitute our realistic pathway forward. The synthesis is intended for clinicians working in infectious diseases, urology, respiratory medicine, and general internal medicine, as well as for clinical microbiologists and pharmacists involved in formulary management.'),

      // ── 2. PHARMACOLOGY ──
      heading1('2. Pharmacology and Mechanism of Action'),
      heading2('2.1 Structural Features and Generations'),
      body('Fluoroquinolones share a bicyclic quinolone core with a fluorine atom at position 6, which markedly enhances antibacterial potency and bioavailability compared with the parent naphthyridine compounds. Structural modifications at positions 1, 7, and 8 of the quinolone ring confer expanded spectrum, altered pharmacokinetics, and differential tissue distribution. The four clinical generations differ primarily in spectrum:'),
      body('First-generation agents (nalidixic acid) target only gram-negative bacteria. Second-generation compounds (ciprofloxacin, norfloxacin, ofloxacin) extend activity to Pseudomonas aeruginosa and expand coverage of gram-negatives. Third-generation fluoroquinolones (levofloxacin) add reliable activity against Streptococcus pneumoniae. Fourth-generation agents (moxifloxacin, gemifloxacin) further improve gram-positive and anaerobic coverage.'),
      heading2('2.2 Dual Topoisomerase Targeting'),
      bodyWithCites('The primary bactericidal mechanism of FQs involves the formation of stable ternary drug-enzyme-DNA complexes with two essential type II topoisomerases: DNA gyrase (a tetramer of GyrA2GyrB2) and topoisomerase IV (a tetramer of ParC2ParE2). These enzymes are responsible for relieving torsional strain during DNA replication and transcription. FQs intercalate at the enzyme-cleaved DNA interface, stabilising a transient double-strand break and preventing relegation. The accumulation of these trapped complexes generates lethal chromosomal fragmentation.', [1]),
      body('DNA gyrase is the primary target in gram-negative bacteria, while topoisomerase IV predominates as the primary target in gram-positive organisms. Agents with dual-target activity - achieving concentrations sufficient to inhibit both enzymes - demonstrate reduced propensity for single-step resistance selection, as simultaneous mutation of both target genes is a low-probability event. This principle has informed the pharmacodynamic rationale for dosing regimens that maintain drug concentrations well above the mutant prevention concentration (MPC).'),
      heading2('2.3 Pharmacodynamic Parameters'),
      body('FQs exhibit concentration-dependent killing, meaning that their antibacterial effect correlates with the ratio of peak drug concentration to the minimum inhibitory concentration (C(max):MIC) and also with the area under the concentration-time curve relative to MIC (AUC:MIC). A 24-hour AUC:MIC ratio exceeding 100-125 for gram-negative pathogens (and > 30-40 for gram-positives) is associated with optimal bactericidal outcomes and reduced resistance emergence. These pharmacodynamic targets guide dose selection and support the use of higher, once-daily dosing regimens over divided lower doses.'),

      // ── 3. RESISTANCE MECHANISMS ──
      heading1('3. Mechanisms of Fluoroquinolone Resistance'),
      body('Resistance to FQs is mechanistically diverse and frequently multifactorial. Three principal categories are recognised: chromosomal target-site mutations, plasmid-mediated resistance determinants, and active efflux-mediated export. In clinical isolates these mechanisms commonly co-occur, producing high-level resistance that cannot be overcome at pharmacologically achievable drug concentrations.'),
      heading2('3.1 Target-Site Mutations: Quinolone Resistance-Determining Regions'),
      bodyWithCites('The most frequently identified mechanism is the acquisition of point mutations within the quinolone resistance-determining regions (QRDRs) of gyrA (encoding GyrA subunit of DNA gyrase) and parC (encoding ParC subunit of topoisomerase IV). The most clinically significant substitutions in E. coli occur at codons 83 and 87 of GyrA (typically Ser83Leu and Asp87Asn/Gly) and at codons 80 and 84 of ParC (Ser80Ile and Glu84Val/Gly). These substitutions reduce the affinity of the drug-enzyme interaction by altering the binding pocket geometry, raising the MIC by 4- to 64-fold per mutation.', [1, 3]),
      body('Stepwise accumulation of QRDR mutations is the dominant pathway to clinical resistance. A single GyrA mutation typically raises the ciprofloxacin MIC from the susceptible range (<0.125 mg/L) into the intermediate zone; a second mutation in GyrA or ParC may breach the clinical breakpoint. The presence of sub-inhibitory drug concentrations during therapy or in environmental niches (animal husbandry, wastewater) creates the selective pressure that favours sequential mutation accumulation. This gradient of selection is the basis for the "mutant selection window" concept, which argues that drug concentrations maintained above the MPC prevent resistant mutant amplification.'),
      body('Mutations in gyrB and parE are less commonly implicated in clinical resistance but contribute incrementally to high-level phenotypes. Reduced affinity in both gyrase and topoisomerase IV confers cross-resistance across the entire FQ class, limiting the utility of switching between agents once resistance is established.'),
      heading2('3.2 Plasmid-Mediated Quinolone Resistance (PMQR)'),
      bodyWithCites('A paradigm shift in understanding FQ resistance came with the discovery of plasmid-mediated quinolone resistance (PMQR) determinants, first described in the late 1990s. Unlike chromosomal mutations, PMQR genes are transmissible horizontally between bacteria of different genera via conjugative plasmids, facilitating rapid intercontinental dissemination. The major PMQR determinants include:', [4]),
      body('Qnr proteins (QnrA, QnrB, QnrC, QnrD, QnrS, QnrVC): pentapeptide repeat proteins that mimic DNA structure and competitively inhibit FQ binding to the topoisomerase-DNA complex. QnrS and QnrB are globally prevalent; the aac(6\')-Ib-cr gene encoding a bifunctional acetyltransferase that modifies the piperazinyl nitrogen of ciprofloxacin and norfloxacin, reducing their antibacterial activity by approximately four-fold; plasmid-borne efflux genes (qepA, oqxAB) that encode dedicated quinolone efflux pumps conferring low-level resistance that acts synergistically with other determinants.'),
      bodyWithCites('A systematic review of PMQR among Enterobacterales in Africa identified the aac(6\')-Ib-cr gene as the most prevalent determinant (32% of isolates with PMQR), followed by qnrS (26%), primarily in E. coli isolates and most commonly against ciprofloxacin. The geographic concentration of studies in West and North Africa underscores critical surveillance gaps in sub-Saharan regions. PMQR genes alone typically confer only low- to moderate-level resistance (4- to 16-fold MIC increase), but their clinical importance lies in their role as resistance "boosters" that facilitate the subsequent selection of high-level QRDR mutants.', [4]),
      heading2('3.3 Efflux Pump Overexpression'),
      bodyWithCites('Active efflux constitutes a third major resistance mechanism, with FQs serving as substrates for several clinically significant resistance-nodulation-division (RND) family efflux systems. The AcrAB-TolC system in Enterobacterales and the MexAB-OprM system in P. aeruginosa are particularly important. These tripartite pumps span both the inner and outer membranes, efficiently extruding FQs and multiple other antibiotic classes simultaneously. Overexpression driven by mutations in regulatory genes (marA, soxS, acrR, mexR) raises FQ MICs two- to eight-fold and co-selects resistance to beta-lactams, chloramphenicol, and tetracyclines.', [3]),
      body('Biofilm formation substantially amplifies efflux-mediated resistance by creating microenvironments of reduced drug penetration, metabolic dormancy (persister cells), and elevated reactive oxygen species scavenging. Persister cells are phenotypically tolerant, non-dividing bacteria that survive antibiotic exposure and reseed infection upon treatment cessation. The interplay between efflux pump upregulation, biofilm physiology, and FQ treatment failure is particularly apparent in device-associated infections and chronic prostatitis.'),
      heading2('3.4 Outer Membrane Permeability Reduction'),
      body('Gram-negative bacteria can supplement the above mechanisms by downregulating the expression of outer membrane porins (OmpF and OmpC in E. coli; OprD in P. aeruginosa) through which hydrophilic FQs gain cellular entry. Although porin loss alone rarely achieves clinical resistance, its combination with efflux overexpression and QRDR mutations creates a multi-layered permeability barrier that profoundly reduces intracellular drug accumulation.'),
      heading2('3.5 FQ Resistance in Specific Pathogens'),
      body('The clinical impact of FQ resistance varies by pathogen. In Neisseria gonorrhoeae, QRDR mutations in gyrA (Ser91Phe, Asp95Gly) and parC (Asp86Asn, Ser87Ile) are now nearly universal among circulating strains in high-income countries, rendering ciprofloxacin unreliable for empirical therapy without susceptibility testing. In Mycobacterium tuberculosis, mutations in gyrA and gyrB underpin fluoroquinolone resistance in multidrug-resistant TB (MDR-TB) and pre-extensively drug-resistant TB (pre-XDR-TB), complicating treatment regimens dependent on levofloxacin and moxifloxacin. In Campylobacter species, which are common causes of food-borne diarrhoea, FQ resistance rates have risen sharply due to point mutations in gyrA, associated with poultry antibiotic use.'),

      // ── 4. GLOBAL EPIDEMIOLOGY ──
      heading1('4. Global Epidemiology and Clinical Burden'),
      heading2('4.1 Urinary Tract Infections'),
      body('Urinary tract infections are arguably the clinical domain where FQ resistance has had the greatest impact, both numerically and strategically. E. coli causes approximately 80-85% of uncomplicated UTIs and remains the organism most frequently implicated in complicated UTIs, pyelonephritis, and catheter-associated infections. A 2026 systematic review and meta-analysis examining global FQ resistance in E. coli UTIs, drawing on data through December 2025, demonstrated using random-effects pooling that ciprofloxacin resistance is widespread across all WHO regions.'),
      body('The WHO 2025 Global Antibiotic Resistance Surveillance Report corroborated this, documenting ciprofloxacin resistance among E. coli isolates at 39.8% in its systematic review synthesis and 39.4% via GLASS network data - a remarkable convergence that increases confidence in these estimates. Resistance to co-trimoxazole (49.1%) and third-generation cephalosporins (39.8%) among the same E. coli isolates indicates that many UTI-causing strains are multiply resistant, severely narrowing oral treatment options.'),
      body('For urologists, FQ resistance in pyelonephritis and prostatitis is particularly consequential, as these indications historically relied heavily on ciprofloxacin and levofloxacin for their superior tissue penetration into the urinary tract parenchyma and prostate stroma. Transrectal prostate biopsy prophylaxis with ciprofloxacin has been associated with rising rates of post-procedural sepsis attributable to resistant rectal carriage, prompting many centres to shift to targeted prophylaxis guided by rectal swab cultures.'),
      heading2('4.2 Respiratory Infections'),
      body('The respiratory fluoroquinolones (levofloxacin, moxifloxacin, gemifloxacin) retain activity against S. pneumoniae, Haemophilus influenzae, and atypical respiratory pathogens including Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae. Resistance among S. pneumoniae remains relatively low in most surveillance datasets, partly attributed to the reduced prescribing pressure from respiratory FQs compared with other antibiotic classes. However, fluoroquinolone-resistant pneumococcal clones have emerged in populations with high rates of prior FQ use, including elderly patients in long-term care facilities. Any escalation of FQ resistance in this pathogen would significantly undermine treatment options for severe community-acquired pneumonia.'),
      heading2('4.3 Sexually Transmitted Infections'),
      body('The emergence of multidrug-resistant Neisseria gonorrhoeae represents one of the most alarming manifestations of FQ resistance globally. FQs were once first-line therapy for gonorrhoea; they are now effectively obsolete in most high-income countries where resistance rates exceed 40-70%. Third-generation cephalosporins (ceftriaxone) represent the current mainstay of therapy, but ceftriaxone-resistant and even extensively drug-resistant strains have been documented, raising the spectre of untreatable gonorrhoea. WHO has classified drug-resistant N. gonorrhoeae as a priority pathogen, and the ongoing epidemic - with an estimated 82 million new infections annually - makes resistance control both medically and epidemiologically urgent.'),
      heading2('4.4 Enteric and Other Systemic Infections'),
      body('In Salmonella typhi and non-typhoidal Salmonella, ciprofloxacin resistance at approximately 38.1% (pooled systematic review) threatens empirical management of enteric fever in endemic regions such as South Asia and sub-Saharan Africa. Fluoroquinolone-resistant Campylobacter, linked to veterinary antibiotic use in poultry production, causes millions of food-borne illness cases annually, frequently requiring azithromycin as the sole remaining oral option. In Pseudomonas aeruginosa, chromosomal QRDR mutations combined with efflux overexpression produce intrinsically reduced FQ susceptibility, compounded in healthcare settings by selection of high-level resistant strains.'),

      // ── 5. ADVERSE EVENTS ──
      heading1('5. Adverse Event Profile: A Clinical Constraint on Prescribing'),
      bodyWithCites('The clinical utility of FQs is further constrained by a well-characterised adverse event profile that goes beyond the gastrointestinal intolerance common to most antibiotic classes. Recognition of rare but serious toxicities has driven successive regulatory restrictions and informs contemporary stewardship guidelines.', [2]),
      heading2('5.1 Musculoskeletal Toxicity'),
      body('Tendinopathy and tendon rupture, most commonly affecting the Achilles tendon, represent the most widely recognised FQ-specific adverse effect. The mechanism involves FQ-mediated inhibition of tenocyte proliferation, induction of matrix metalloproteinases, and mitochondrial dysfunction. Risk factors include advanced age (over 60 years), concomitant corticosteroid use, and renal impairment. Black-box warning labelling has been mandatory in the United States since 2008. Although the absolute risk remains modest (estimated 15-40 per 100,000 courses), the consequences of tendon rupture in elderly or physically active patients can be severe and potentially irreversible.'),
      heading2('5.2 Neurological Toxicity'),
      body('Peripheral neuropathy, characterised by sensorimotor deficits that may persist or become permanent after drug discontinuation, has been reported with all FQ class members. The postulated mechanism involves FQ-mediated mitochondrial toxicity and oxidative stress in peripheral nerve fibres, analogous to the mechanism underlying other FQ tissue toxicities. Central nervous system effects including insomnia, anxiety, psychosis, and confusional states are recognised, particularly in elderly patients.'),
      heading2('5.3 Cardiovascular and Aortic Risks'),
      body('Pharmacoepidemiology studies have reported a small but statistically significant association between FQ use and QTc prolongation, which carries risk of torsades de pointes in predisposed patients. Concurrent use of other QTc-prolonging agents, pre-existing cardiac disease, and hypokalaemia are established co-risk factors. More recently, population-based cohort analyses have identified an association between FQ exposure and aortic aneurysm and dissection, attributed to inhibition of matrix metalloproteinase-2 degradation in aortic connective tissue. The FDA updated prescribing information to include this risk in 2018.'),
      heading2('5.4 Clinical Implications for Prescribing'),
      body('These toxicity data have reinforced regulatory and stewardship guidance to reserve FQs for clinical scenarios where they provide clear benefit not achievable with safer alternatives. For uncomplicated cystitis in women, pivmecillinam, fosfomycin, nitrofurantoin, and trimethoprim are preferred first-line options. For community-acquired pneumonia, beta-lactam plus macrolide regimens retain preference over respiratory fluoroquinolones in non-severe disease. A systematic review and comparative analysis published in 2026 demonstrated that oral beta-lactams are non-inferior to FQs for complicated UTIs in appropriate patients, offering a viable de-escalation strategy.'),

      // ── 6. STEWARDSHIP ──
      heading1('6. Antimicrobial Stewardship: Preserving Fluoroquinolone Efficacy'),
      heading2('6.1 Principles of Antimicrobial Stewardship'),
      body('Antimicrobial stewardship programmes (ASPs) aim to optimise the selection, dosing, route, and duration of antibiotic therapy to improve patient outcomes while minimising the unintended consequences of antibiotic use, including resistance selection, Clostridioides difficile infection, and drug toxicity. For FQs, stewardship has increasingly moved beyond general "use only when necessary" messaging toward more targeted, evidence-based intervention frameworks.'),
      heading2('6.2 Formulary Restriction and Prior-Authorisation'),
      body('Institutional restriction of FQs requiring infectious diseases consultation or pharmacist approval before dispensing has demonstrated reproducible reductions in prescribing volume without adverse impact on clinical outcomes in multiple observational studies. Tiered restriction policies that distinguish between high-value indications (e.g. Legionella pneumonia, MDR gram-negative infections confirmed on susceptibility testing) and lower-value reflexive prescribing (e.g. uncomplicated UTI in a non-pregnant, non-elderly woman) provide a practical framework for clinician guidance.'),
      heading2('6.3 Local Antibiogram Guidance and Empirical Therapy Thresholds'),
      body('The IDSA and EMA recommend that FQs should not be used for empirical therapy of UTIs when local E. coli resistance rates exceed 20%, given the probability that a significant proportion of infections will fail first-line empirical treatment. Institutions maintaining up-to-date antibiograms stratified by infection type, patient population (community vs. hospital-acquired), and organism allow clinicians to make rational empirical choices. Electronic health record-integrated clinical decision support (CDS) tools that surface real-time resistance prevalence data at the point of prescribing have shown promise in reducing inappropriate FQ initiation.'),
      heading2('6.4 Targeted Prophylaxis in Urology'),
      body('The shift from blanket ciprofloxacin prophylaxis to culture-directed prophylaxis for transrectal ultrasound-guided prostate biopsy exemplifies stewardship innovation driven by resistance epidemiology. Pre-biopsy rectal swab screening with targeted antibiotic selection based on identified rectal flora has reduced post-biopsy infection rates in centres with high background FQ resistance. The transition to transperineal biopsy approaches - which bypass the rectum entirely - also eliminates the need for FQ prophylaxis in many institutions.'),
      heading2('6.5 One Health and Agricultural Stewardship'),
      body('The "One Health" framework recognises that human, animal, and environmental health are interconnected in the ecology of antimicrobial resistance. FQ use in food-producing animals, particularly poultry, has been directly linked to the emergence of fluoroquinolone-resistant Campylobacter and Salmonella strains that spread to humans through the food chain. The European Union banned the use of fluoroquinolones as growth promoters in 2003, and subsequent regulatory restrictions on veterinary FQ use in various jurisdictions have been associated with measurable declines in resistance rates in foodborne pathogens. Expansion of these policies globally, particularly in countries with high volumes of antibiotic use in agriculture, is an essential stewardship priority.'),
      heading2('6.6 Education and Behavioural Change'),
      body('Patient and prescriber education remains fundamental. Prescriber education initiatives that highlight the adverse-event profile of FQs alongside their resistance implications have demonstrated modest but reproducible reductions in prescribing frequency. Patient-facing materials explaining why a prescription for trimethoprim rather than ciprofloxacin is appropriate for their UTI improve adherence to the preferred agent and reduce the "antibiotic pressure" that selects for resistance at the population level.'),

      // ── 7. INNOVATION ──
      heading1('7. Innovation: Next-Generation Topoisomerase Inhibitors and Beyond'),
      heading2('7.1 The Case for Novel Topoisomerase Inhibitors'),
      body('Given the mechanistic elegance of topoisomerase inhibition as an antibacterial strategy, pharmaceutical research has continued to pursue novel agents that inhibit the same enzymatic targets as FQs but through distinct binding modes that escape classical QRDR-mediated resistance. Two classes have advanced furthest in clinical development: the triazaacenaphthylene gepotidacin and the spiropyrimidinetrione zoliflodacin.'),
      heading2('7.2 Gepotidacin'),
      bodyWithCites('Gepotidacin (formerly GSK2140944) is a first-in-class bacterial type II topoisomerase inhibitor that belongs to the triazaacenaphthylene structural class. It binds to a novel site on DNA gyrase distinct from the FQ binding interface, generating a mechanism of action that is unaffected by mutations at GyrA Ser83 or Asp87. Phase 3 clinical trial data have demonstrated non-inferiority to nitrofurantoin for uncomplicated urinary tract infections and non-inferiority to the comparator arm for uncomplicated gonorrhoea, including activity against ciprofloxacin-resistant strains of N. gonorrhoeae. Its unique binding mechanism confers activity against organisms with pre-existing QRDR mutations, and it is currently pending FDA approval for both UTI and gonorrhoea.', [5]),
      heading2('7.3 Zoliflodacin'),
      bodyWithCites('Zoliflodacin (formerly AZD0914) is a spiropyrimidinetrione antibiotic that inhibits bacterial type II topoisomerases through a distinct mechanism involving a Mg2+-mediated interaction with the GyrB subunit - the TOPRIM domain - rather than the GyrA interface targeted by FQs. Phase 3 trial data have demonstrated its efficacy against uncomplicated gonorrhoea, including multidrug-resistant strains, with a favourable safety profile as a single oral dose. Regulatory approval for gonorrhoea is anticipated, with potential for expansion into other indications if further development proceeds.', [5]),
      heading2('7.4 Monoclonal Antibodies and Biologics'),
      bodyWithCites('The expanding toolkit of biologics for infectious diseases includes bactericidal monoclonal antibodies targeting surface-exposed antigens of N. gonorrhoeae and other pathogens. Preclinical studies have identified human monoclonal antibodies with bactericidal activity in animal infection models, and their potential as passive immunoprophylactics in high-risk populations is under investigation. While monoclonal antibody therapies face cost and administration route barriers compared with oral antibiotics, they represent a meaningful addition to the innovation pipeline for infections caused by organisms with no remaining oral options.', [5]),
      heading2('7.5 Bacteriophage Therapy'),
      body('Bacteriophage therapy - the therapeutic use of viruses that specifically infect and lyse bacteria - has undergone a renaissance following several high-profile compassionate use cases and an expanding body of early-phase clinical data. Phages are inherently resistant-resistant in that each phage is tailored to specific bacterial surface receptors, and phage cocktails can be formulated to circumvent bacterial phage-resistance mutations. Their activity against biofilm-embedded bacteria, where conventional antibiotics including FQs fail, makes them particularly attractive for device-associated infections and chronic MDR infections. Regulatory frameworks for phage therapy remain in evolution, but several countries have established compassionate use pathways.'),
      heading2('7.6 Anti-Biofilm and Resistance-Breaking Strategies'),
      body('Pharmacological strategies targeting bacterial biofilm formation and persistence represent a complementary approach to conventional antibiotics. Efflux pump inhibitors (EPIs), which block RND-family pumps such as AcrAB-TolC, can restore FQ activity against pump-overexpressing isolates in vitro. Compounds including phenyl-arginine-beta-naphthylamide (PAbetaN) and newer phenylalanine-arginine derivatives have demonstrated in vitro synergy with FQs against resistant gram-negatives, though clinical translation has been hindered by toxicity and pharmacokinetic limitations. Anti-virulence strategies targeting quorum sensing, type III secretion systems, and biofilm matrix synthesis offer additional mechanistic avenues that do not directly exert bactericidal pressure and therefore may carry lower resistance selection potential.'),
      heading2('7.7 Artificial Intelligence in Drug Discovery'),
      body('Machine learning and artificial intelligence (AI) platforms are increasingly applied to antibiotic drug discovery, offering the potential to identify novel scaffolds, predict compound activity against resistant phenotypes, and optimise molecular properties including membrane permeability and metabolic stability. AI-assisted identification of small molecules with activity against N. gonorrhoeae has been reported in preclinical settings. While AI-discovered compounds are still early in development, the acceleration of lead identification and optimisation that these platforms offer is genuinely significant in a field historically constrained by the pharmaceutical economics of antibiotic development.'),

      // ── 8. TABLES ──
      heading1('8. Summary Tables'),
      heading2('Table 1. Principal Fluoroquinolone Resistance Mechanisms and Clinical Implications'),
      spacer(),
      buildTable(
        ['Mechanism', 'Molecular Basis', 'Resistance Level', 'Transferable?', 'Clinical Impact'],
        [
          ['QRDR mutations (gyrA, parC)', 'Point mutations at Ser83/Asp87 (GyrA) and Ser80/Glu84 (ParC)', 'High (>128-fold MIC increase with multiple mutations)', 'No (chromosomal)', 'Class-wide FQ resistance; limits switching'],
          ['PMQR - Qnr proteins', 'Plasmid-encoded pentapeptide repeat proteins shield topoisomerase', 'Low-moderate (4-16 fold)', 'Yes (conjugative plasmid)', 'Facilitates selection of QRDR mutants'],
          ['PMQR - aac(6\')-Ib-cr', 'Acetyltransferase modifies ciprofloxacin/norfloxacin piperazinyl N', 'Low-moderate (2-4 fold)', 'Yes', 'Synergistic with other mechanisms'],
          ['Efflux pump overexpression (AcrAB-TolC, MexAB-OprM)', 'Regulatory mutations derepress tripartite RND efflux systems', 'Moderate (2-8 fold)', 'Partially (some genes plasmid-borne)', 'Multi-drug co-resistance; poor tissue penetration'],
          ['Outer membrane porin loss', 'Transcriptional downregulation of OmpF/OmpC/OprD', 'Low alone; high in combination', 'No', 'Compounds efflux-mediated resistance']
        ]
      ),
      spacer(),
      heading2('Table 2. Stewardship Interventions and Emerging Therapeutic Alternatives'),
      spacer(),
      buildTable(
        ['Strategy', 'Target', 'Evidence Base', 'Status'],
        [
          ['Formulary restriction / prior authorisation', 'FQ prescribing volume', 'Multiple observational studies showing reduced volume without outcome harm', 'Widely implemented in tertiary centres'],
          ['Electronic CDS at point of prescribing', 'Empirical FQ selection for UTI/RTI', 'Pre/post studies demonstrating inappropriate prescribing reduction', 'Increasingly deployed in HIS systems'],
          ['Local antibiogram-driven empirical therapy guidelines', 'Threshold-based FQ restriction (>20% local resistance)', 'IDSA/EMA guideline recommendation', 'Guideline-recommended; implementation variable'],
          ['Rectal swab-targeted prophylaxis (urology)', 'Post-biopsy sepsis from resistant rectal flora', 'RCT-level evidence supporting superiority over blanket FQ prophylaxis', 'Recommended by EAU guidelines'],
          ['Gepotidacin', 'FQ-resistant UTI and gonorrhoea', 'Phase 3 trial data; non-inferior to nitrofurantoin/standard of care', 'Pending FDA approval'],
          ['Zoliflodacin', 'Multidrug-resistant N. gonorrhoeae', 'Phase 3 trial data; single-dose oral efficacy', 'Pending regulatory approval'],
          ['Bacteriophage therapy', 'Biofilm-associated and MDR infections', 'Case series and early-phase clinical data; compassionate use approvals', 'Investigational; compassionate use pathways active'],
          ['Efflux pump inhibitors', 'Restore FQ activity against pump-overexpressing strains', 'In vitro and animal data; limited clinical trials', 'Investigational; clinical translation pending']
        ]
      ),
      spacer(),

      // ── 9. DISCUSSION ──
      heading1('9. Discussion'),
      body('Fluoroquinolone resistance is neither a monolithic problem nor a problem confined to a single infectious disease specialty. Its mechanistic complexity - encompassing chromosomal target-site mutations, horizontally transferable plasmid genes, and adaptive efflux overexpression - means that resistance emerges and spreads through multiple parallel pathways simultaneously. The epidemiological data from global surveillance networks and meta-analyses present a sobering picture: for the most widely used FQ, ciprofloxacin, approximately four in ten E. coli isolates from UTIs are now resistant. This rate surpasses the 20% threshold at which empirical FQ use for UTIs is considered inappropriate by most guidelines, rendering ciprofloxacin unreliable as an empirical first-line agent in many clinical contexts.'),
      body('The adverse-event profile of FQs compounds the stewardship imperative. When resistance considerations alone might permit FQ use, the risk of tendinopathy, peripheral neuropathy, aortic aneurysm, and QTc prolongation demands individualised risk-benefit assessment. The cumulative effect of successive FDA and EMA regulatory actions has been to define a much narrower "appropriate FQ use" space than was recognised even a decade ago. This narrowing is appropriate: FQs are genuinely important agents whose efficacy must be preserved for the infections where they offer clinically meaningful advantages.'),
      body('Stewardship strategies have demonstrated meaningful impact on FQ prescribing volume and, in some settings, on rates of resistant isolates. However, stewardship alone is insufficient. Resistance genes are now deeply embedded in gram-negative bacterial populations globally, including in environmental and agricultural reservoirs that are largely beyond the reach of hospital-based ASPs. The "One Health" dimension of FQ resistance - encompassing veterinary prescribing, food chain transmission, and wastewater as a resistance reservoir - requires policy responses at a scale that individual institutions cannot achieve in isolation.'),
      body('The innovation landscape offers genuine grounds for cautious optimism. Gepotidacin and zoliflodacin represent the first genuinely new topoisomerase inhibitors to advance to late-phase clinical trials in decades, and their distinct binding mechanisms confer activity against strains harbouring classical QRDR mutations. If regulatory approval is granted and real-world effectiveness mirrors trial outcomes, these agents will provide meaningful additions to the therapeutic arsenal for two of the most resistance-burdened clinical scenarios: complicated UTI and multidrug-resistant gonorrhoea. Phage therapy and AI-assisted drug discovery are further upstream but represent directions with distinct mechanistic rationales that could diversify future antimicrobial options beyond conventional small-molecule antibiotics.'),
      body('Several important uncertainties and gaps in knowledge deserve acknowledgement. The clinical pharmacodynamics of gepotidacin and zoliflodacin in populations beyond the clinical trial setting - including in patients with renal impairment, complex pharmacological profiles, or infections caused by organisms with novel resistance determinants - have not been fully characterised. The emergence of resistance to these novel agents in clinical use must be anticipated and monitored proactively. For bacteriophage therapy, the absence of harmonised regulatory frameworks and the inherent challenge of producing phage preparations for widely prevalent, genotypically diverse pathogens remain barriers to routine clinical implementation.'),

      // ── 10. CONCLUSION ──
      heading1('10. Conclusion'),
      body('Fluoroquinolone resistance is an established global threat to clinical practice across infectious diseases, urology, respiratory medicine, and public health. The mechanistic pluralism of resistance - target-site mutation, PMQR gene transmission, and efflux pump overexpression - demands a correspondingly multifaceted response. This response must integrate mechanistic understanding, evidenced stewardship practice, systemic policy action under the One Health framework, and sustained investment in therapeutic innovation.'),
      body('Clinicians must apply FQs judiciously, guided by local resistance data, patient-specific risk factors for toxicity, and institutional stewardship policy. Microbiologists and pharmacists should ensure that antibiogram data are current, accessible, and integrated into prescribing decision support systems. Regulatory and agricultural authorities need to maintain and strengthen restrictions on FQ use outside human medicine. Pharmaceutical and academic researchers should continue to advance gepotidacin, zoliflodacin, and the broader pipeline of mechanistically novel antibacterial agents toward clinical availability.'),
      body('FQs have served medicine well for over thirty years. With disciplined stewardship and the emergence of novel topoisomerase inhibitors that circumvent classical resistance mechanisms, the therapeutic class they pioneered may yet contribute meaningfully to infectious disease management for decades to come - provided the clinical community acts decisively to preserve what remains.'),

      // ── DECLARATIONS ──
      heading1('Declarations'),
      body('Conflicts of interest: The authors declare no conflicts of interest.'),
      body('Funding: This narrative review received no external funding.'),
      body('Ethics statement: Not applicable (review article; no primary data collected).'),
      body('Author contributions: [To be completed per journal requirements]'),

      // ── REFERENCES ──
      new Paragraph({ children: [new PageBreak()] }),
      heading1('References'),
      refEntry(1, 'Bush NG, Diez-Santos I, Abbott LR, Maxwell A. Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance. Molecules. 2020;25(23):5662. doi:10.3390/molecules25235662. PMID: 33271787'),
      refEntry(2, 'Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. Aust Prescr. 2021;44(5):161-164. doi:10.18773/austprescr.2021.035. PMID: 34728881'),
      refEntry(3, 'Nasrollahian S, Graham JP, Halaji M. A review of the mechanisms that confer antibiotic resistance in pathotypes of E. coli. Front Cell Infect Microbiol. 2024;14:1387497. doi:10.3389/fcimb.2024.1387497. PMID: 38638826'),
      refEntry(4, 'Abubakar J, Sabitu MZ, Muhammad KD, et al. Plasmid-Mediated Fluoroquinolone Resistance among Enterobacterales in Africa: Systematic Review. West Afr J Med. 2024. PMID: 38788127'),
      refEntry(5, 'Ram S, Gill D, Rice PA. Combatting antimicrobial-resistant Neisseria gonorrhoeae: new antibiotics and the pipeline of antigonococcal therapeutics. Curr Opin Infect Dis. 2026;39(1). doi:10.1097/QCO.0000000000001170. PMID: 41452091'),
      refEntry(6, 'Kunz Coyne AJ, Bouchard J, Durham SH, et al. Oral beta-Lactams for Complicated Urinary Tract Infections: A Systematic Review and Point-Counterpoint Comparison with Trimethoprim/Sulfamethoxazole and Fluoroquinolones. Pharmacotherapy. 2026. PMID: 41693075'),
      refEntry(7, 'Thompson D, Xu J, Ischia J, Bolton D. Fluoroquinolone resistance in urinary tract infections: Epidemiology, mechanisms of action and management strategies. BJUI Compass. 2022;4(1):4-11. doi:10.1002/bco2.286'),
      refEntry(8, 'World Health Organization. Global Antibiotic Resistance Surveillance Report 2025. Geneva: WHO; 2025. Available at: https://media.tghn.org/medialibrary/2025/10/Global_antibiotic_esistance_Surveillance_report_2025.pdf'),
      refEntry(9, 'Mlynarczyk-Bonikowska B, Kowalewski C, Krolak-Ulinska A, et al. Molecular Mechanisms of Drug Resistance and Epidemiology of Multidrug-Resistant Variants of Neisseria gonorrhoeae. Int J Mol Sci. 2022;23(18):10499. doi:10.3390/ijms231810499. PMID: 36142410'),
      refEntry(10, 'Tasanapak K, Sitthisak S, Kitti T, et al. A systematic review and meta-analysis of the global prevalence of fluoroquinolone resistant Morganella morganii clinical isolates. Sci Rep. 2025;15:34746. doi:10.1038/s41598-025-18294-2'),

    ]
  }]
});

Packer.toBuffer(doc).then(buffer => {
  fs.writeFileSync('/home/daytona/workspace/fq-review/FQ_Resistance_Narrative_Review.docx', buffer);
  console.log('SUCCESS: Document written.');
}).catch(err => {
  console.error('ERROR:', err);
  process.exit(1);
});

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/fq-review/build_review.js'

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/fq-review/build_review.js'

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/fq-review/build_review.js'

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/fq-review/build_review.js'

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/fq-review/build_review.js'

const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  HeadingLevel, AlignmentType, WidthType, VerticalAlign,
  PageNumber, PageBreak, Header, Footer
} = require('docx');
const fs = require('fs');

// ── Helpers ───────────────────────────────────────────────────────────────────
const heading1 = (text) =>
  new Paragraph({ heading: HeadingLevel.HEADING_1, children: [new TextRun({ text, bold: true })] });

const heading2 = (text) =>
  new Paragraph({ heading: HeadingLevel.HEADING_2, children: [new TextRun({ text, bold: true })] });

const body = (text) =>
  new Paragraph({ children: [new TextRun({ text, font: 'Arial', size: 24 })], spacing: { after: 160 } });

const spacer = () => new Paragraph({ children: [new TextRun('')], spacing: { after: 120 } });

const cite = (num) => new TextRun({ text: `[${num}]`, font: 'Arial', size: 18, superScript: true });

const bodyC = (text, refs) =>
  new Paragraph({
    children: [new TextRun({ text, font: 'Arial', size: 24 }), ...refs.map(r => cite(r))],
    spacing: { after: 160 }
  });

const refEntry = (num, text) =>
  new Paragraph({ children: [new TextRun({ text: `${num}. ${text}`, font: 'Arial', size: 22 })], spacing: { after: 120 } });

const buildRichTable = (headers, rows) => {
  const headerRow = new TableRow({
    tableHeader: true,
    children: headers.map(h => new TableCell({
      shading: { fill: '1F3864', type: 'clear' },
      margins: { top: 100, bottom: 100, left: 120, right: 120 },
      children: [new Paragraph({ alignment: AlignmentType.CENTER, children: [new TextRun({ text: h, font: 'Arial', size: 18, bold: true, color: 'FFFFFF' })] })],
      verticalAlign: VerticalAlign.CENTER
    }))
  });
  const dataRows = rows.map((row, ri) =>
    new TableRow({
      children: row.map((cell, ci) => new TableCell({
        shading: ci === 0 ? { fill: '2E5496', type: 'clear' } : ri % 2 === 0 ? { fill: 'EEF2FA', type: 'clear' } : { fill: 'FFFFFF', type: 'clear' },
        margins: { top: 80, bottom: 80, left: 120, right: 120 },
        children: [new Paragraph({ children: [new TextRun({ text: cell, font: 'Arial', size: 18, bold: ci === 0, color: ci === 0 ? 'FFFFFF' : '000000' })] })],
        verticalAlign: VerticalAlign.CENTER
      }))
    })
  );
  return new Table({ width: { size: 100, type: WidthType.PERCENTAGE }, rows: [headerRow, ...dataRows] });
};

// ── Document ──────────────────────────────────────────────────────────────────
const doc = new Document({
  styles: {
    default: { document: { run: { font: 'Arial', size: 24 } } },
    paragraphStyles: [
      { id: 'Heading1', name: 'Heading 1', basedOn: 'Normal', next: 'Normal', quickFormat: true,
        run: { size: 36, bold: true, font: 'Arial', color: '1F3864' },
        paragraph: { spacing: { before: 360, after: 240 }, outlineLevel: 0 } },
      { id: 'Heading2', name: 'Heading 2', basedOn: 'Normal', next: 'Normal', quickFormat: true,
        run: { size: 28, bold: true, font: 'Arial', color: '2E5496' },
        paragraph: { spacing: { before: 280, after: 160 }, outlineLevel: 1 } }
    ]
  },
  sections: [{
    properties: {
      page: { size: { width: 12240, height: 15840 }, margin: { top: 1440, right: 1440, bottom: 1440, left: 1440 } }
    },
    headers: {
      default: new Header({ children: [new Paragraph({
        alignment: AlignmentType.RIGHT,
        children: [new TextRun({ text: 'Narrative Review | Fluoroquinolone Resistance', font: 'Arial', size: 18, color: '666666' })]
      })] })
    },
    footers: {
      default: new Footer({ children: [new Paragraph({
        alignment: AlignmentType.CENTER,
        children: [
          new TextRun({ text: 'Page ', font: 'Arial', size: 18, color: '666666' }),
          new TextRun({ children: [PageNumber.CURRENT], font: 'Arial', size: 18, color: '666666' }),
          new TextRun({ text: ' of ', font: 'Arial', size: 18, color: '666666' }),
          new TextRun({ children: [PageNumber.TOTAL_PAGES], font: 'Arial', size: 18, color: '666666' })
        ]
      })] })
    },
    children: [

      // ── TITLE ──
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: 480, after: 240 },
        children: [new TextRun({ text: 'Beyond First-Line Defence: Addressing Fluoroquinolone Resistance Through Mechanistic Insight, Stewardship and Innovation', bold: true, font: 'Arial', size: 40, color: '1F3864' })]
      }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 120 },
        children: [new TextRun({ text: 'A Narrative Review', font: 'Arial', size: 24, italics: true, color: '444444' })] }),
      spacer(),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Mr. Salih Jabbar J  B.Sc., D.M.L.T.', font: 'Arial', size: 22, bold: true, color: '1F3864' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'M.D Candidate, Department of General Medicine', font: 'Arial', size: 22, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Kuban State Medical University, Krasnodar, Russia', font: 'Arial', size: 22, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Email: dr.salihjabbar2023ru@gmail.com', font: 'Arial', size: 22, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Running title: Fluoroquinolone Resistance: Mechanisms, Stewardship and Innovation', font: 'Arial', size: 22, italics: true, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Word count: ~7,200 | Tables: 3 | Date: July 2026', font: 'Arial', size: 22, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Keywords: fluoroquinolones; antimicrobial resistance; DNA gyrase; antimicrobial stewardship; gepotidacin; zoliflodacin; plasmid-mediated resistance', font: 'Arial', size: 22, italics: true, color: '555555' })] }),

      // ── ABSTRACT ──
      new Paragraph({ children: [new PageBreak()] }),
      heading1('Abstract'),
      new Paragraph({ spacing: { after: 160 }, children: [
        new TextRun({ text: 'Background: ', bold: true, font: 'Arial', size: 24 }),
        new TextRun({ text: "Fluoroquinolones (FQs) - think ciprofloxacin, levofloxacin, moxifloxacin - spent thirty-plus years as the clinician's Swiss Army knife. Broad spectrum, easy oral dosing, penetrates almost everywhere. But that popularity came at a price. Resistance is now rampant. Ciprofloxacin fails to work against around 40% of the E. coli strains causing urinary tract infections in many parts of the world, and N. gonorrhoeae? FQs are essentially useless against it.", font: 'Arial', size: 24 })
      ]}),
      new Paragraph({ spacing: { after: 160 }, children: [
        new TextRun({ text: 'Objectives: ', bold: true, font: 'Arial', size: 24 }),
        new TextRun({ text: "This review pulls together what we actually know - the pharmacology, the molecular tricks bacteria use to dodge FQs, the side-effect baggage that limits prescribing, and the stewardship strategies that can slow the rot. It also looks hard at what's coming next: new drugs, new approaches, a potential way out.", font: 'Arial', size: 24 })
      ]}),
      new Paragraph({ spacing: { after: 160 }, children: [
        new TextRun({ text: 'Methods: ', bold: true, font: 'Arial', size: 24 }),
        new TextRun({ text: 'Narrative review. PubMed, MEDLINE, WHO surveillance databases, literature from 2015 through July 2026. Focused on resistance mechanisms, stewardship outcomes, and the therapeutic pipeline.', font: 'Arial', size: 24 })
      ]}),
      new Paragraph({ spacing: { after: 160 }, children: [
        new TextRun({ text: 'Results: ', bold: true, font: 'Arial', size: 24 }),
        new TextRun({ text: "Bacteria resist FQs three main ways: they mutate the drug's targets (QRDR mutations in gyrA/gyrB, parC/parE), they pick up resistance genes on plasmids that spread between species like gossip at a conference (PMQR genes: qnr, aac(6')-Ib-cr, qepA/oqxAB), and they pump the drug back out before it can do any damage (AcrAB-TolC, MexAB-OprM efflux systems). WHO 2025 data puts ciprofloxacin resistance in UTI-causing E. coli at about 39-40% globally. Stewardship programmes - restriction policies, antibiogram-guided thresholds, clinical decision tools - do make a measurable dent. And two genuinely novel topoisomerase inhibitors, gepotidacin and zoliflodacin, sailed through phase 3 trials and are queued for FDA approval.", font: 'Arial', size: 24 })
      ]}),
      new Paragraph({ spacing: { after: 160 }, children: [
        new TextRun({ text: 'Conclusions: ', bold: true, font: 'Arial', size: 24 }),
        new TextRun({ text: "Fixing this isn't a one-lever problem. You need mechanistic insight to find new targets, disciplined stewardship to preserve what's left, and serious investment in next-generation agents. Clinicians, microbiologists, pharmacists, and public health folks all have skin in the game.", font: 'Arial', size: 24 })
      ]}),

      // ── 1. INTRODUCTION ──
      new Paragraph({ children: [new PageBreak()] }),
      heading1('1. Introduction'),
      body("Here's a bit of irony worth sitting with. The very things that made fluoroquinolones so useful - that sweeping broad spectrum, the pill-form convenience, the ease of prescribing for almost anything - are exactly what drove us into the resistance crisis we're now trying to manage. It's a bit like a motorway that works brilliantly until everyone discovers it at once."),
      body("FQs earned their place over three decades. Nalidixic acid opened the door in the 1960s, and successive fluorinated generations walked through it: ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin. By the early 2000s they were among the most prescribed antibiotics on the planet. And why not? They killed bacteria with real efficiency, absorbed well orally (70-100% bioavailability for most), penetrated tissues most antibiotics can't touch - the prostate, the CNS, the lungs - and covered gram-negatives, atypicals, and, for the later respiratory members, gram-positives too."),
      bodyC("So FQs ended up first- or second-line for UTIs, community-acquired pneumonia, infectious diarrhoea, gonorrhoea, prostatitis, prophylaxis in immunocompromised patients. The list goes on. Commercially and clinically, they were a triumph.", [1]),
      body("Then the resistance data started rolling in. WHO's 2025 Global Antibiotic Resistance Surveillance Report put ciprofloxacin resistance in E. coli UTI isolates at 39.8% by pooled systematic review - nearly identical to the 39.4% from the GLASS network. That convergence isn't reassuring; it's alarming. Salmonella spp. clocked in at 38.1% ciprofloxacin resistance - not a trivial number if you're trying to treat enteric fever empirically in South Asia or sub-Saharan Africa."),
      bodyC("The regulators noticed too. The FDA and EMA have issued successive black-box warnings covering tendinopathy, tendon rupture, peripheral neuropathy, and aortic aneurysm. The FDA pulled FQs from uncomplicated UTIs and acute sinusitis in 2016 - a tacit admission that the risk-benefit maths no longer added up for routine use.", [2]),
      body("This review takes FQ resistance apart from three angles: the molecular biology driving it, the epidemiological scale of it, and the stewardship and innovation strategies that give us a realistic shot at managing it. It's aimed at clinicians - infectious disease, urology, respiratory, internal medicine - alongside the microbiologists and pharmacists shaping formulary decisions."),

      // ── 2. PHARMACOLOGY ──
      heading1('2. Pharmacology and Mechanism of Action'),
      heading2('2.1 Structural Features and Generations'),
      body("All FQs share a bicyclic quinolone core with a fluorine atom at position 6 - that fluorine substitution is what boosted potency and bioavailability beyond the original naphthyridine template. Tinker with positions 1, 7, and 8 and you shift the spectrum, alter tissue distribution, tweak the pharmacokinetics. Four clinical generations fell out of that tinkering."),
      body("First-generation (nalidixic acid): gram-negatives only, limited clinical role. Second-generation (ciprofloxacin, norfloxacin, ofloxacin): gram-negative breadth including Pseudomonas aeruginosa - this is where clinical FQs really took off. Third-generation (levofloxacin): adds reliable pneumococcal cover. Fourth-generation (moxifloxacin, gemifloxacin): pushes into gram-positives and anaerobes. Each step expanded the spectrum; each step also expanded the antibiotic pressure on bacterial populations."),
      heading2('2.2 Dual Topoisomerase Targeting'),
      bodyC("FQs kill bacteria by hijacking the enzymes that manage DNA topology - DNA gyrase (GyrA2GyrB2) and topoisomerase IV (ParC2ParE2). Think of these enzymes as the machinery that uncoils your DNA's supercoiled tension during replication. FQs wedge into the interface between enzyme and cleaved DNA, locking in a double-strand break that can't be repaired. DNA fragments accumulate. The cell dies.", [1]),
      body("In gram-negatives, gyrase is the primary target. In gram-positives, topoisomerase IV takes that role. Agents that hit both enzymes hard at clinically achievable concentrations make resistance selection much harder - you'd need simultaneous mutations in two different genes, which is statistically unlikely. That dual-target principle is the scientific rationale for dosing strategies that keep drug concentrations above the mutant prevention concentration (MPC), not just above the MIC."),
      heading2('2.3 Pharmacodynamic Parameters'),
      body("FQs kill in a concentration-dependent fashion. The metrics that predict outcome are C(max):MIC and AUC:MIC. For gram-negatives you want a 24-hour AUC:MIC above 100-125; for gram-positives, 30-40 will often do. What does this mean practically? It supports higher, once-daily doses over split lower doses - you're trying to overwhelm the bacteria with peak exposure, not just maintain a trough. Get the pharmacodynamics wrong and you're not just undertreating; you're selecting for resistant mutants."),

      // ── 3. RESISTANCE MECHANISMS ──
      heading1('3. Mechanisms of Fluoroquinolone Resistance'),
      body("FQ resistance isn't one thing. It's a collection of molecular strategies - some chromosomal, some transmissible, some phenotypic - that bacteria have assembled over decades of antibiotic pressure. And they rarely use just one. In the clinical isolates giving us the most trouble, three or four mechanisms run simultaneously, stacking up MIC increases until no achievable drug concentration can touch the pathogen."),
      heading2('3.1 Target-Site Mutations: Quinolone Resistance-Determining Regions'),
      bodyC("The most common resistance mechanism starts with a single point mutation in gyrA - specifically at codon 83 (Ser83Leu) or codon 87 (Asp87Asn/Gly) in E. coli. That mutation tweaks the drug-binding pocket geometry just enough to reduce FQ affinity, nudging the ciprofloxacin MIC from susceptible (<0.125 mg/L) up into the intermediate range. One more mutation - either another gyrA change or one in parC at Ser80 or Glu84 - and you've breached the clinical breakpoint. The bacteria are now clinically resistant.", [1, 3]),
      body("This stepwise accumulation is the engine of resistance selection. Sub-inhibitory FQ concentrations - the stuff circulating in a patient who's been given an inadequate dose, or in soil and water near a chicken farm - sit right in the middle of the mutant selection window. They don't kill the bacteria; they select the ones that already carry partial resistance. Give it time and a few more antibiotic courses, and you've enriched a fully resistant population."),
      body("Less commonly, mutations in gyrB and parE add incremental MIC increases. Once resistance involves both gyrase and topoisomerase IV, you've got class-wide FQ resistance - switching from ciprofloxacin to levofloxacin to moxifloxacin accomplishes nothing."),
      heading2('3.2 Plasmid-Mediated Quinolone Resistance (PMQR)'),
      bodyC("The late 1990s brought a nasty surprise: resistance genes that lived on plasmids and could jump between bacterial species. That horizontal gene transfer changes the equation entirely. It's not just that one patient's E. coli becomes resistant - those genes can move into Klebsiella, Salmonella, Enterobacter, and spread intercontinentally on conjugative plasmids.", [4]),
      body("The main PMQR players are: Qnr proteins (QnrA, QnrB, QnrC, QnrD, QnrS, QnrVC) - pentapeptide repeat proteins that mimic DNA and physically shield the topoisomerase from FQ attack. QnrS and QnrB show up everywhere globally. Then there's aac(6')-Ib-cr, a modified acetyltransferase that chemically modifies ciprofloxacin and norfloxacin's piperazinyl nitrogen, clipping their antibacterial activity by roughly four-fold. And finally plasmid-borne efflux genes, qepA and oqxAB, that pump quinolones out before they accumulate to lethal concentrations."),
      bodyC("A systematic review of PMQR among Enterobacterales in Africa found aac(6')-Ib-cr as the most prevalent gene (32% of PMQR-positive isolates), followed by qnrS at 26%, almost always in E. coli. Now, PMQR genes alone usually can't get MICs above the clinical breakpoint - they raise MIC four- to sixteen-fold, not a hundred-fold. But that's not the point. Their real danger is that they lower the threshold for subsequent QRDR mutation selection. They're the on-ramp to high-level resistance.", [4]),
      heading2('3.3 Efflux Pump Overexpression'),
      bodyC("Think of efflux pumps as biological bouncers. AcrAB-TolC in Enterobacterales, MexAB-OprM in Pseudomonas - these tripartite RND-family systems span both bacterial membranes and physically expel FQs before they can accumulate to a lethal concentration inside the cell. Normally they're controlled by regulatory repressors. Mutate marA, soxS, or acrR, and those repressors lose their grip. Pump expression shoots up. FQ MICs double, quadruple, octuple.", [3]),
      body("The multi-drug dimension is critical here. These pumps aren't FQ-specific - they extrude beta-lactams, chloramphenicol, and tetracyclines simultaneously. So an FQ-resistant pump overexpressor is often resistant to half your formulary. And then there's biofilm. Bacteria in a biofilm matrix slow their metabolism, express efflux pumps at high levels, and spawn persister cells - dormant survivors that sit out an antibiotic course, then repopulate the infection the moment treatment stops. Chronic prostatitis and device-associated infections are poster children for this failure mode."),
      heading2('3.4 Outer Membrane Permeability Reduction'),
      body("Gram-negative bacteria can add one more layer of defence: downregulating the outer membrane porins (OmpF, OmpC in E. coli; OprD in Pseudomonas) that FQs normally diffuse through to reach their targets. Porin loss alone isn't usually enough - it bumps MICs modestly. But stack it on top of efflux overexpression and QRDR mutations and you get a near-impenetrable barrier. Intracellular drug accumulation drops to the point where even high-dose regimens fail."),
      heading2('3.5 FQ Resistance in Specific Pathogens'),
      body("Pathogen matters, obviously. In N. gonorrhoeae, GyrA mutations Ser91Phe and Asp95Gly are now so common in high-income countries that ciprofloxacin shouldn't be used empirically without a susceptibility result - full stop. In M. tuberculosis, gyrA and gyrB mutations drive FQ resistance in MDR-TB and pre-XDR-TB, complicating the levofloxacin and moxifloxacin-based regimens that represent last-line options for many patients. In Campylobacter - the most common bacterial cause of food-borne illness in many regions - gyrA mutations linked directly to poultry antibiotic use have pushed FQ resistance rates up sharply; azithromycin is often the only oral option left."),

      // ── 4. EPIDEMIOLOGY ──
      heading1('4. Global Epidemiology and Clinical Burden'),
      heading2('4.1 Urinary Tract Infections'),
      body("UTIs are where FQ resistance hits hardest in terms of sheer numbers. E. coli causes 80-85% of uncomplicated UTIs, and when ciprofloxacin fails against it roughly four times in ten, the entire empirical treatment paradigm for one of medicine's most common infections collapses. A 2026 meta-analysis of global FQ resistance in E. coli UTIs, covering data through December 2025, confirmed widespread resistance across all WHO regions using random-effects pooling."),
      body("The WHO 2025 surveillance report puts ciprofloxacin resistance at 39.8% by systematic review and 39.4% via GLASS - the fact that two independent methodologies land within 0.4% of each other should remove any lingering doubt. And it's not just ciprofloxacin: co-trimoxazole resistance in the same E. coli isolates hits 49.1%, third-generation cephalosporins 39.8%. Many UTI strains are now genuinely multi-drug resistant, and oral options are dwindling."),
      body("For urologists, the implications are direct and practical. Ciprofloxacin prophylaxis for transrectal prostate biopsy is generating post-procedural sepsis from resistant rectal E. coli at unacceptable rates. The field is shifting toward pre-biopsy rectal swab screening with targeted prophylaxis - or, better yet, transperineal approaches that skip the rectum entirely."),
      heading2('4.2 Respiratory Infections'),
      body("The respiratory FQs - levofloxacin, moxifloxacin, gemifloxacin - have so far held their ground against S. pneumoniae, Legionella, Mycoplasma, and Chlamydophila. Resistance in pneumococci remains relatively low, partly because respiratory FQs are prescribed less reflexively than ciprofloxacin. But that can't be taken for granted. FQ-resistant pneumococcal clones have appeared in nursing home populations with heavy prior FQ use. Lose respiratory FQ efficacy against pneumococcus and the management of severe CAP gets significantly harder."),
      heading2('4.3 Sexually Transmitted Infections'),
      body("Gonorrhoea is a cautionary tale worth studying. FQs were first-line for N. gonorrhoeae. Now they're obsolete in most high-income countries, with resistance rates north of 40-70%. Ceftriaxone holds the line today - but ceftriaxone-resistant strains exist, and XDR gonococcal infections have been documented. WHO lists drug-resistant N. gonorrhoeae as a priority pathogen. With 82 million new gonococcal infections globally per year, the consequences of a truly untreatable epidemic aren't hypothetical."),
      heading2('4.4 Enteric and Other Systemic Infections'),
      body("Ciprofloxacin resistance in Salmonella at 38.1% undermines empirical enteric fever management in endemic regions. Fluoroquinolone-resistant Campylobacter, driven substantially by veterinary antibiotic use in poultry, leaves azithromycin as the lone oral agent in many cases. And P. aeruginosa - intrinsically less susceptible, with layered efflux and QRDR mutations on top - produces some of the most therapeutically hostile gram-negative infections encountered in hospital practice."),

      // ── 5. ADVERSE EVENTS ──
      heading1('5. Adverse Event Profile: A Clinical Constraint on Prescribing'),
      bodyC("Resistance alone doesn't explain why prescribing FQs is increasingly restricted. The toxicity profile has become a genuine clinical problem, going well beyond the GI upset you'd expect with most antibiotics.", [2]),
      heading2('5.1 Musculoskeletal Toxicity'),
      body("Achilles tendon rupture from a course of ciprofloxacin. It sounds implausible until you've seen it. FQs inhibit tenocyte proliferation, trigger matrix metalloproteinase activity, and disrupt mitochondrial function in tendon tissue. The absolute risk is modest - roughly 15-40 per 100,000 treatment courses - but for an elderly patient on corticosteroids, those odds feel less comfortable. US black-box warnings have been mandatory since 2008. The consequence can be permanent."),
      heading2('5.2 Neurological Toxicity'),
      body("Peripheral neuropathy - sensorimotor deficits that may never fully resolve after stopping the drug - has been documented with every FQ class member. The postulated mechanism is mitochondrial toxicity and oxidative stress in peripheral nerve fibres, which isn't surprising given FQs' known effects on mitochondrial DNA (a structural quirk shared with bacterial DNA). CNS effects - insomnia, anxiety, frank psychosis, confusion - are recognised too, particularly in older patients."),
      heading2('5.3 Cardiovascular and Aortic Risks'),
      body("QTc prolongation is on the label, and the risk of torsades de pointes in patients already on other QTc-prolonging drugs or with baseline cardiac disease is real. More recently, population cohort analyses picked up an association between FQ exposure and aortic aneurysm and dissection - attributed to FQ-mediated inhibition of MMP-2 degradation in aortic connective tissue. The FDA updated labelling in 2018. It's a rare event, but the aorta is an unforgiving location for a drug side effect."),
      heading2('5.4 Clinical Implications for Prescribing'),
      body("All of this adds up to a clear message: FQs should be used when the clinical situation genuinely warrants them, not because they're convenient. For uncomplicated cystitis in otherwise healthy women, fosfomycin, nitrofurantoin, pivmecillinam, and trimethoprim are preferred. For non-severe CAP, a beta-lactam plus macrolide combination outperforms respiratory FQs on the risk-benefit balance. A 2026 systematic review confirmed oral beta-lactams are non-inferior to FQs for complicated UTIs in appropriate patients - so the 'FQ or nothing' assumption doesn't hold."),

      // ── 6. STEWARDSHIP ──
      heading1('6. Antimicrobial Stewardship: Preserving Fluoroquinolone Efficacy'),
      heading2('6.1 Principles of Antimicrobial Stewardship'),
      body("Antimicrobial stewardship isn't just an audit exercise or a box to tick on a quality dashboard. It's the practical application of resistance science to day-to-day prescribing. For FQs specifically, stewardship has had to evolve from broad messaging ('use antibiotics wisely') to targeted, data-driven frameworks that actually change prescribing behaviour."),
      heading2('6.2 Formulary Restriction and Prior Authorisation'),
      body("Requiring infectious diseases consultation or pharmacist approval before an FQ can be dispensed - tiered by indication - works. Multiple observational studies show reproducible reductions in FQ prescribing volume without any measurable harm to patient outcomes. The key is distinguishing genuinely high-value indications (confirmed MDR gram-negative infection, Legionella pneumonia) from reflexive over-prescribing (a healthy young woman with a simple UTI who walks out with ciprofloxacin because it was the path of least resistance for the prescriber)."),
      heading2('6.3 Local Antibiogram Guidance and Empirical Therapy Thresholds'),
      body("IDSA and EMA guidance is unambiguous: if local E. coli resistance exceeds 20%, FQs shouldn't be used empirically for UTIs. That threshold is already breached in many settings. Up-to-date antibiograms stratified by infection type and patient population give clinicians what they need to make rational choices. Electronic clinical decision support tools embedded in the EHR and capable of surfacing real-time local resistance data at the point of prescribing are showing genuine promise in reducing inappropriate initiation."),
      heading2('6.4 Targeted Prophylaxis in Urology'),
      body("Pre-biopsy rectal swab culture followed by targeted antibiotic prophylaxis has changed the post-prostate biopsy sepsis story considerably. And transperineal biopsy - which skips the rectum entirely - eliminates the need for FQ prophylaxis altogether in institutions that've adopted it. These are tangible stewardship wins driven by resistance data rather than habit."),
      heading2('6.5 One Health and Agricultural Stewardship'),
      body("You can't steward your way out of a problem that's partly generated in a chicken shed. FQ use in food-producing animals has directly seeded fluoroquinolone-resistant Campylobacter and Salmonella into the human food chain. The EU banned FQs as growth promoters in 2003; resistance in foodborne pathogens declined measurably in jurisdictions that followed with veterinary restrictions. Globally, agricultural FQ use remains enormous. Until that changes, hospital stewardship programmes are fighting on one front of a multi-front war."),
      heading2('6.6 Education and Behavioural Change'),
      body("Patient expectations, prescriber habits, time pressure in a busy clinic - these aren't irrational; they're human. Prescriber education that connects FQ toxicity risk to an individual patient (not just an abstract population) alongside resistance data tends to move behaviour more effectively than resistance messaging alone. Patient-facing communication explaining why trimethoprim for a UTI is the right choice - not a lesser choice - improves adherence and reduces the antibiotic pressure that feeds resistance at the population level."),

      // ── 7. INNOVATION ──
      heading1('7. Innovation: Next-Generation Topoisomerase Inhibitors and Beyond'),
      heading2('7.1 The Case for Novel Topoisomerase Inhibitors'),
      body("Topoisomerase inhibition is still a brilliant antibacterial strategy. The problem isn't the target - it's the binding site. Classical FQs all dock at roughly the same interface, and that's where QRDR mutations land. The logical response is to find compounds that inhibit the same enzymes through structurally distinct binding modes that QRDR mutations simply can't obstruct. Two drugs have actually made it through phase 3 trials doing exactly this."),
      heading2('7.2 Gepotidacin'),
      bodyC("Gepotidacin (formerly GSK2140944) is a triazaacenaphthylene - a genuinely new structural class. It binds DNA gyrase at a site distinct from the classical FQ interface, so GyrA Ser83 and Asp87 mutations? Irrelevant to its activity. Phase 3 data showed non-inferiority to nitrofurantoin for uncomplicated UTIs and non-inferiority for uncomplicated gonorrhoea, including ciprofloxacin-resistant N. gonorrhoeae strains. It's pending FDA approval for both indications. If approved and used sensibly, this is potentially a meaningful addition to the UTI and STI treatment arsenal.", [5]),
      heading2('7.3 Zoliflodacin'),
      bodyC("Zoliflodacin (formerly AZD0914) works through the GyrB TOPRIM domain rather than the GyrA subunit targeted by FQs. Different mechanism, different binding site, same enzymatic target. Phase 3 efficacy against multidrug-resistant gonorrhoea has been demonstrated with a single oral dose and a clean safety profile. Regulatory approval is anticipated. Whether its use stays confined to gonorrhoea or expands - that depends on future development choices and, frankly, on pharmaceutical economics.", [5]),
      heading2('7.4 Monoclonal Antibodies and Biologics'),
      bodyC("Monoclonal antibodies for bacterial infections are still niche, but the concept is sound. Bactericidal human mAbs against surface-exposed antigens of N. gonorrhoeae have shown activity in preclinical animal models. They're not a pill you can hand to a patient in a community clinic, but for high-risk populations facing infections with no remaining oral options, passive immunoprophylaxis via biologics could become a legitimate strategy.", [5]),
      heading2('7.5 Bacteriophage Therapy'),
      body("Phage therapy is having a genuine moment. The logic is appealing: phages are highly specific, they can penetrate and kill bacteria within biofilms where antibiotics fail, and you can engineer phage cocktails to stay ahead of phage-resistance mutations. Several high-profile compassionate use cases - MDR P. aeruginosa, intractable Staphylococcal infections - attracted significant attention. Early-phase clinical data are accumulating. The regulatory path remains messy in most jurisdictions, but compassionate frameworks exist. For device-associated MDR infections with no conventional options, phage therapy is already being used."),
      heading2('7.6 Anti-Biofilm and Resistance-Breaking Strategies'),
      body("Efflux pump inhibitors that restore FQ activity against pump-overexpressing strains work beautifully in vitro. PAβN and related phenylalanine-arginine derivatives are the canonical examples. Clinical translation has stalled - toxicity, poor pharmacokinetics, the usual barriers. Anti-virulence strategies (quorum sensing inhibitors, type III secretion blockers, biofilm matrix disruptors) are mechanistically distinct enough that they may not drive resistance selection at the same rate as bactericidal drugs. They're years from the clinic, but the underlying science is credible."),
      heading2('7.7 Artificial Intelligence in Drug Discovery'),
      body("AI in antibiotic discovery has moved well beyond hype. Machine learning platforms now predict compound activity against resistant phenotypes, optimise membrane permeability and metabolic stability, and can screen virtual compound libraries at a scale no medicinal chemist team could match. AI-assisted identification of small molecules active against N. gonorrhoeae has been published in preclinical settings. The pharmaceutical economics of antibiotic development remain a structural problem - short treatment courses, generic competition, thin margins - but AI is genuinely compressing the lead-identification and optimisation timeline, which matters in a field where the pipeline has been chronically thin."),

      // ── DISCUSSION ──
      heading1('8. Discussion'),
      body("What does the resistance data actually tell us? Roughly speaking: we're four mutations away from clinical FQ failure in a typical E. coli, and bacteria are acquiring those mutations under the selective pressure we've been applying for thirty years. The PMQR genes spreading on plasmids across continents aren't the immediate killers - they're the primers that make the next mutation easier to select. It's a slow-motion catastrophe playing out in microbiology labs globally, one MIC result at a time."),
      body("The toxicity story complicates the picture further. Resistance alone might justify a narrow, indication-specific role for FQs. But when you layer on tendon rupture, irreversible peripheral neuropathy, aortic dissection, and QTc prolongation, the space where an FQ is both the best available agent and acceptably safe shrinks considerably. The FDA didn't restrict FQs from UTIs and sinusitis out of excessive caution - it did so because safer alternatives exist and the risk-benefit maths had shifted."),
      body("Stewardship programmes genuinely work, but they're playing defence. They can reduce volume, guide empirical choice, and slow resistance accumulation in controlled healthcare settings. They can't reach the veterinary practices and agricultural operations generating the resistance reservoir in the environment. One Health isn't a metaphor; it's an operational necessity. Until agricultural FQ use is brought under comparable regulatory discipline globally, hospital stewardship is containing a problem it can't fully solve."),
      body("Gepotidacin and zoliflodacin are the most concrete grounds for optimism in the near term. Two genuinely novel topoisomerase inhibitors, mechanistically distinct from FQs, with phase 3 efficacy against resistance-burdened pathogens. They're not panaceas - resistance to novel agents can and will emerge with use, and that has to be monitored from day one. But they represent real progress after a decade in which the antimicrobial pipeline had very little to offer for gram-negative infections specifically."),
      body("There are honest gaps to acknowledge. The clinical pharmacodynamics of gepotidacin and zoliflodacin outside the trial populations - complex patients, renal impairment, unusual resistance genotypes - aren't fully characterised. Phage therapy's promise hasn't yet translated into broad clinical availability or harmonised regulatory approval. And the AI-discovered compounds generating excitement in preclinical labs face the same brutal economics that have stalled antibiotic development for decades. Optimism should be calibrated, not uncritical."),

      // ── CONCLUSION ──
      heading1('9. Conclusion'),
      body("FQ resistance isn't a future problem. It's a present one. Roughly 40% of E. coli UTI isolates are already ciprofloxacin-resistant in many parts of the world. N. gonorrhoeae has essentially shed FQ susceptibility. MDR-TB treatment is constrained by FQ resistance in gyrA and gyrB. The mechanisms driving this - QRDR mutations, PMQR gene transmission, efflux pump overexpression - are well understood. So are the solutions, at least in outline."),
      body("Clinicians need to apply FQs where they genuinely offer something that safer alternatives can't. Microbiologists and pharmacists need to keep antibiogram data current and integrated into prescribing workflows. Regulators and agricultural authorities need to close the veterinary loophole. Researchers and pharmaceutical companies need to get gepotidacin and zoliflodacin to market, and then keep investing in whatever comes after them."),
      body("FQs have served medicine well for over thirty years. With disciplined stewardship and the arrival of genuinely novel topoisomerase inhibitors, this antibiotic class might remain clinically useful for another generation. But only if the clinical community acts - now, deliberately, and in concert."),

      // ── DECLARATIONS ──
      heading1('Declarations'),
      body('Conflicts of interest: The authors declare no conflicts of interest.'),
      body('Funding: This narrative review received no external funding.'),
      body('Ethics statement: Not applicable (review article; no primary data collected).'),

      // ── TABLE 1 ──
      new Paragraph({ children: [new PageBreak()] }),
      heading1('Table 1. Principal Fluoroquinolone Resistance Mechanisms and Clinical Implications'),
      spacer(),
      buildRichTable(
        ['Mechanism', 'Molecular Basis', 'Resistance Level', 'Transferable?', 'Clinical Impact'],
        [
          ['QRDR mutations (gyrA, parC)', 'Point mutations at Ser83/Asp87 (GyrA) and Ser80/Glu84 (ParC)', 'High (>128-fold MIC with multiple mutations)', 'No (chromosomal)', 'Class-wide FQ resistance; limits agent switching'],
          ["PMQR - Qnr proteins", 'Plasmid-encoded pentapeptide repeat proteins shield topoisomerase', 'Low-moderate (4-16 fold)', 'Yes (conjugative plasmid)', 'Primes bacteria for QRDR mutation selection'],
          ["PMQR - aac(6')-Ib-cr", "Acetyltransferase modifies ciprofloxacin/norfloxacin piperazinyl N", 'Low-moderate (2-4 fold)', 'Yes', 'Synergistic with other mechanisms; aminoglycoside co-resistance'],
          ['Efflux pump overexpression (AcrAB-TolC, MexAB-OprM)', 'Regulatory mutations derepress RND tripartite efflux systems', 'Moderate (2-8 fold)', 'Partially', 'Multi-drug co-resistance; biofilm persistence'],
          ['Outer membrane porin loss', 'Downregulation of OmpF/OmpC/OprD', 'Low alone; high combined', 'No', 'Compounds efflux resistance; impairs tissue penetration']
        ]
      ),
      spacer(),

      // ── TABLE 2 ──
      heading1('Table 2. Stewardship Interventions and Emerging Therapeutic Alternatives'),
      spacer(),
      buildRichTable(
        ['Strategy', 'Target', 'Evidence Base', 'Status'],
        [
          ['Formulary restriction / prior authorisation', 'FQ prescribing volume', 'Multiple observational studies; no outcome harm', 'Widely implemented in tertiary centres'],
          ['EHR-integrated clinical decision support', 'Inappropriate empirical FQ selection', 'Pre/post studies; measurable inappropriate prescribing reduction', 'Increasingly deployed'],
          ['Antibiogram-guided empirical thresholds (>20% local resistance)', 'Empirical UTI FQ use', 'IDSA/EMA guideline recommendation', 'Recommended; implementation variable'],
          ['Targeted prophylaxis in urology (rectal swab-guided)', 'Post-biopsy sepsis from resistant flora', 'RCT-level evidence; superiority over blanket FQ prophylaxis', 'EAU guideline-recommended'],
          ['Gepotidacin', 'FQ-resistant UTI and gonorrhoea', 'Phase 3 data; non-inferior to nitrofurantoin/SOC', 'Pending FDA approval'],
          ['Zoliflodacin', 'MDR N. gonorrhoeae', 'Phase 3 single-dose oral efficacy', 'Pending regulatory approval'],
          ['Bacteriophage therapy', 'Biofilm-associated and MDR infections', 'Case series, early-phase data, compassionate use', 'Investigational'],
          ['Efflux pump inhibitors', 'Restore FQ activity against pump-overexpressing strains', 'Strong in vitro; limited clinical trials', 'Investigational']
        ]
      ),
      spacer(),

      // ── TABLE 3 ──
      heading1('Table 3. Comprehensive Comparison of Fluoroquinolone Resistance Mechanisms and Clinical Outcomes'),
      spacer(),
      new Paragraph({ spacing: { after: 180 }, children: [new TextRun({ text: 'MIC = minimum inhibitory concentration; QRDR = quinolone resistance-determining region; PMQR = plasmid-mediated quinolone resistance; RND = resistance-nodulation-division; HGT = horizontal gene transfer.', font: 'Arial', size: 20, italics: true, color: '555555' })] }),
      buildRichTable(
        ['Mechanism', 'Genetic Basis', 'Key Genes / Loci', 'MIC Impact', 'Horizontally Transferable?', 'Organisms Most Affected', 'Co-resistance Profile', 'Detection Method', 'Clinical Outcome', 'Therapeutic Implication'],
        [
          ['QRDR - GyrA', 'Chromosomal point mutations in gyrA', 'gyrA Ser83Leu, Asp87Asn (E. coli); Ser91Phe, Asp95Gly (N. gonorrhoeae)', '4-32 fold per mutation; >128-fold combined', 'No', 'E. coli, Salmonella, N. gonorrhoeae, Campylobacter, P. aeruginosa', 'FQ class-wide cross-resistance only', 'Sanger/WGS QRDR sequencing; PCR-RFLP', 'Empirical FQ failure; treatment failure UTI, gonorrhoea, enteric fever', 'Susceptibility-guided therapy; gepotidacin retains activity'],
          ['QRDR - ParC / ParE', 'Chromosomal mutations in parC and parE', 'parC Ser80Ile, Glu84Val (E. coli); Asp86Asn, Ser87Ile (N. gonorrhoeae)', 'Additive to GyrA; alone 2-8 fold', 'No', 'E. coli, S. aureus, S. pneumoniae, N. gonorrhoeae', 'Class-wide FQ when combined with GyrA', 'WGS; targeted QRDR sequencing; phenotypic MIC', 'Compounded failure; persister enrichment', 'Dual-target novel agents (gepotidacin, zoliflodacin) unaffected'],
          ['PMQR - Qnr proteins', 'Plasmid-encoded pentapeptide repeat proteins mimic DNA', 'qnrA, qnrB, qnrS (prevalent); qnrC, qnrD, qnrVC', 'Low-moderate 4-16 fold', 'Yes - conjugative plasmids; intercontinental HGT', 'Enterobacterales broadly', 'Co-located with ESBL genes (blaCTX-M), carbapenemases', 'PCR for qnr genes; WGS', 'Lowers barrier to QRDR selection; MDR amplification', 'Infection control critical; screen for ESBL co-production'],
          ["PMQR - aac(6')-Ib-cr", 'Modified aminoglycoside acetyltransferase acetylates FQ piperazinyl N', "aac(6')-Ib-cr; most prevalent PMQR gene (~32%)", '2-4 fold for cipro/norfloxacin; levofloxacin unaffected', 'Yes - integrons, conjugative plasmids', 'E. coli, K. pneumoniae; prevalent in Africa, Asia', 'Aminoglycoside co-resistance; frequent CTX-M ESBL co-location', 'PCR allele-specific primers; WGS', 'Reduces ciprofloxacin efficacy; synergistic with QRDR mutations', 'Levofloxacin/moxifloxacin not substrates; importance is MDR co-selection'],
          ['PMQR - efflux genes (qepA, oqxAB)', 'Plasmid-borne RND/MFS efflux pumps', 'qepA (MFS; E. coli); oqxAB (RND; E. coli, K. pneumoniae)', 'Moderate 4-32 fold; oqxAB multi-FQ class', 'Yes - plasmids and transposons', 'E. coli, K. pneumoniae', 'Chloramphenicol, trimethoprim co-resistance (oqxAB)', 'PCR; WGS; EPI phenotypic assay (PAβN)', 'High-level resistance when combined with QRDR; spreads in institutions', 'No approved EPIs; infection control to limit plasmid spread'],
          ['AcrAB-TolC overexpression', 'Regulatory mutations derepress tripartite RND efflux', 'marA, soxS, rob; acrR; ramA (Salmonella/Klebsiella)', 'Moderate 2-8 fold', 'No (chromosomal); partial for some genes', 'E. coli, Salmonella, K. pneumoniae, Enterobacter', 'Broad MDR: beta-lactams, chloramphenicol, tetracyclines, biocides', 'Phenotypic EPI assay; RT-PCR acrAB; WGS', 'Biofilm treatment failure; persister enrichment; chronic prostatitis refractory', 'Anti-biofilm agents; rifampicin combination; EPI (investigational)'],
          ['MexAB-OprM overexpression (Pseudomonas)', 'Regulatory mutations in mexR, nalC, nalD', 'mexR; nalC; nalD; nfxB (MexCD)', 'High intrinsic + 4-16 fold additional; often >64 mg/L cipro MIC', 'No (chromosomal)', 'P. aeruginosa', 'XDR risk: anti-pseudomonal beta-lactams, carbapenems, aminoglycosides', 'WGS; MIC; EPI assay', 'HAP/VAP failure; bacteraemia mortality; CF exacerbations refractory to FQ', 'Combination beta-lactam/aminoglycoside; colistin-based; phage therapy for chronic'],
          ['Outer membrane porin loss', 'Transcriptional repression or inactivation of porins', 'ompF, ompC (E. coli); oprD (P. aeruginosa); ompK35/ompK36 (K. pneumoniae)', '2-4 fold alone; multiplicative with efflux', 'No', 'E. coli, K. pneumoniae, P. aeruginosa', 'Carbapenem co-resistance (OprD loss in Pseudomonas)', 'Outer membrane protein profiling; WGS; proteomics', 'Compounds efflux resistance; FQ tissue penetration impaired', 'Contributing factor; dose escalation ineffective; combination required'],
          ['GyrB / ParE mutations', 'QRDR mutations in gyrase B and topoisomerase IV E subunits', 'gyrB Asp426Asn, Lys447Glu; parE Leu445His, Ser458Trp', 'Moderate 4-16 fold; significant combined with GyrA/ParC', 'No', 'P. aeruginosa, S. aureus, M. tuberculosis (gyrB)', 'FQ class-wide; gyrB in M. tuberculosis co-selects aminocoumarin resistance', 'WGS; targeted gyrB/parE QRDR sequencing', 'MDR-TB FQ resistance; complicates levofloxacin/moxifloxacin regimens', 'Routine gyrB sequencing recommended by WHO for TB drug resistance testing'],
          ['Biofilm / persister cells', 'Phenotypic adaptation; biofilm matrix + dormant persister cell formation', 'rpoS, relA, spoT; mqsR, hipA; pel, psl, alg (biofilm matrix)', 'Not MIC-based; persisters survive 100-1000x MIC; biofilm MIC 10-1000x planktonic', 'No (phenotypic)', 'P. aeruginosa (CF), S. aureus, E. coli (chronic UTI), Enterococcus', 'Tolerance to all antibiotic classes; not detected by standard MIC', 'MBEC assay; time-kill kinetics; confocal microscopy', 'Chronic/recurrent infections: prostatitis, CAUTI, VAP, osteomyelitis; FQ monotherapy fails consistently', 'Device removal; rifampicin anti-persister combination; phage therapy; anti-biofilm agents']
        ]
      ),
      spacer(),
      new Paragraph({ spacing: { after: 240 }, children: [new TextRun({ text: 'Abbreviations: CAUTI = catheter-associated UTI; CF = cystic fibrosis; ESBL = extended-spectrum beta-lactamase; FQ = fluoroquinolone; HAP/VAP = hospital-acquired/ventilator-associated pneumonia; HGT = horizontal gene transfer; MBEC = minimum biofilm eradication concentration; MDR = multidrug-resistant; MDR-TB = multidrug-resistant tuberculosis; MFS = major facilitator superfamily; MIC = minimum inhibitory concentration; MPC = mutant prevention concentration; PAβN = phenylalanine-arginine beta-naphthylamide; PMQR = plasmid-mediated quinolone resistance; QRDR = quinolone resistance-determining region; RND = resistance-nodulation-division; WGS = whole-genome sequencing.', font: 'Arial', size: 18, italics: true, color: '555555' })] }),

      // ── REFERENCES ──
      new Paragraph({ children: [new PageBreak()] }),
      heading1('References'),
      refEntry(1, 'Bush NG, Diez-Santos I, Abbott LR, Maxwell A. Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance. Molecules. 2020;25(23):5662. PMID: 33271787'),
      refEntry(2, 'Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. Aust Prescr. 2021;44(5):161-164. PMID: 34728881'),
      refEntry(3, 'Nasrollahian S, Graham JP, Halaji M. A review of the mechanisms that confer antibiotic resistance in pathotypes of E. coli. Front Cell Infect Microbiol. 2024;14:1387497. PMID: 38638826'),
      refEntry(4, 'Abubakar J, Sabitu MZ, Muhammad KD, et al. Plasmid-Mediated Fluoroquinolone Resistance among Enterobacterales in Africa: Systematic Review. West Afr J Med. 2024. PMID: 38788127'),
      refEntry(5, 'Ram S, Gill D, Rice PA. Combatting antimicrobial-resistant Neisseria gonorrhoeae: new antibiotics and the pipeline of antigonococcal therapeutics. Curr Opin Infect Dis. 2026. PMID: 41452091'),
      refEntry(6, 'Kunz Coyne AJ, et al. Oral beta-Lactams for Complicated UTIs: A Systematic Review. Pharmacotherapy. 2026. PMID: 41693075'),
      refEntry(7, 'Thompson D, Xu J, Ischia J, Bolton D. Fluoroquinolone resistance in UTIs: Epidemiology, mechanisms and management. BJUI Compass. 2022;4(1):4-11.'),
      refEntry(8, 'World Health Organization. Global Antibiotic Resistance Surveillance Report 2025. Geneva: WHO; 2025.'),
      refEntry(9, 'Mlynarczyk-Bonikowska B, et al. Molecular Mechanisms of Drug Resistance in N. gonorrhoeae. Int J Mol Sci. 2022;23(18):10499. PMID: 36142410'),
      refEntry(10, 'Tasanapak K, et al. Global prevalence of fluoroquinolone resistant Morganella morganii. Sci Rep. 2025;15:34746.')

    ]
  }]
});

Packer.toBuffer(doc).then(buffer => {
  fs.writeFileSync('/home/daytona/workspace/fq-review/FQ_Resistance_Review_REWRITTEN.docx', buffer);
  console.log('SUCCESS');
}).catch(err => { console.error(err); process.exit(1); });

const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  HeadingLevel, AlignmentType, WidthType, VerticalAlign,
  PageNumber, PageBreak, Header, Footer
} = require('docx');
const fs = require('fs');

// ── Helpers ───────────────────────────────────────────────────────────────────
const h1 = t => new Paragraph({ heading: HeadingLevel.HEADING_1, children: [new TextRun({ text: t, bold: true })] });
const h2 = t => new Paragraph({ heading: HeadingLevel.HEADING_2, children: [new TextRun({ text: t, bold: true })] });
const b = t => new Paragraph({ children: [new TextRun({ text: t, font: 'Arial', size: 24 })], spacing: { after: 160 } });
const sp = () => new Paragraph({ children: [new TextRun('')], spacing: { after: 120 } });
const sup = n => new TextRun({ text: `[${n}]`, font: 'Arial', size: 18, superScript: true });
const bc = (t, refs) => new Paragraph({ children: [new TextRun({ text: t, font: 'Arial', size: 24 }), ...refs.map(sup)], spacing: { after: 160 } });
const ref = (n, t) => new Paragraph({ children: [new TextRun({ text: `${n}. ${t}`, font: 'Arial', size: 22 })], spacing: { after: 120 } });

const richTable = (headers, rows) => new Table({
  width: { size: 100, type: WidthType.PERCENTAGE },
  rows: [
    new TableRow({
      tableHeader: true,
      children: headers.map(h => new TableCell({
        shading: { fill: '1F3864', type: 'clear' },
        margins: { top: 100, bottom: 100, left: 120, right: 120 },
        children: [new Paragraph({ alignment: AlignmentType.CENTER, children: [new TextRun({ text: h, font: 'Arial', size: 18, bold: true, color: 'FFFFFF' })] })],
        verticalAlign: VerticalAlign.CENTER
      }))
    }),
    ...rows.map((row, ri) => new TableRow({
      children: row.map((cell, ci) => new TableCell({
        shading: ci === 0 ? { fill: '2E5496', type: 'clear' } : ri % 2 === 0 ? { fill: 'EEF2FA', type: 'clear' } : { fill: 'FFFFFF', type: 'clear' },
        margins: { top: 80, bottom: 80, left: 120, right: 120 },
        children: [new Paragraph({ children: [new TextRun({ text: cell, font: 'Arial', size: 18, bold: ci === 0, color: ci === 0 ? 'FFFFFF' : '000000' })] })],
        verticalAlign: VerticalAlign.CENTER
      }))
    }))
  ]
});

// ── Document ──────────────────────────────────────────────────────────────────
const doc = new Document({
  styles: {
    default: { document: { run: { font: 'Arial', size: 24 } } },
    paragraphStyles: [
      { id: 'Heading1', name: 'Heading 1', basedOn: 'Normal', next: 'Normal', quickFormat: true,
        run: { size: 36, bold: true, font: 'Arial', color: '1F3864' },
        paragraph: { spacing: { before: 360, after: 240 }, outlineLevel: 0 } },
      { id: 'Heading2', name: 'Heading 2', basedOn: 'Normal', next: 'Normal', quickFormat: true,
        run: { size: 28, bold: true, font: 'Arial', color: '2E5496' },
        paragraph: { spacing: { before: 280, after: 160 }, outlineLevel: 1 } }
    ]
  },
  sections: [{
    properties: { page: { size: { width: 12240, height: 15840 }, margin: { top: 1440, right: 1440, bottom: 1440, left: 1440 } } },
    headers: { default: new Header({ children: [new Paragraph({ alignment: AlignmentType.RIGHT, children: [new TextRun({ text: 'Narrative Review | Phimosis: Clinical Evaluation and Treatment', font: 'Arial', size: 18, color: '666666' })] })] }) },
    footers: { default: new Footer({ children: [new Paragraph({ alignment: AlignmentType.CENTER, children: [new TextRun({ text: 'Page ', font: 'Arial', size: 18, color: '666666' }), new TextRun({ children: [PageNumber.CURRENT], font: 'Arial', size: 18, color: '666666' }), new TextRun({ text: ' of ', font: 'Arial', size: 18, color: '666666' }), new TextRun({ children: [PageNumber.TOTAL_PAGES], font: 'Arial', size: 18, color: '666666' })] })] }) },
    children: [

      // ── TITLE ──
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { before: 480, after: 240 },
        children: [new TextRun({ text: 'Physiologic and Pathologic Phimosis: A Review of Clinical Evaluation and Treatment Options', bold: true, font: 'Arial', size: 40, color: '1F3864' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 120 },
        children: [new TextRun({ text: 'A Narrative Review', font: 'Arial', size: 24, italics: true, color: '444444' })] }),
      sp(),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Mr. Salih Jabbar J  B.Sc., D.M.L.T.', font: 'Arial', size: 22, bold: true, color: '1F3864' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'M.D Candidate, Department of General Medicine', font: 'Arial', size: 22, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Kuban State Medical University, Krasnodar, Russia', font: 'Arial', size: 22, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Email: dr.salihjabbar2023ru@gmail.com', font: 'Arial', size: 22, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Running title: Phimosis: Physiologic vs. Pathologic - Evaluation and Management', font: 'Arial', size: 22, italics: true, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Word count: ~6,500 | Tables: 3 | Date: July 2026', font: 'Arial', size: 22, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Keywords: phimosis; physiologic phimosis; pathologic phimosis; balanitis xerotica obliterans; lichen sclerosus; circumcision; topical steroids; preputioplasty; foreskin; prepuce', font: 'Arial', size: 22, italics: true, color: '555555' })] }),

      // ── ABSTRACT ──
      new Paragraph({ children: [new PageBreak()] }),
      h1('Abstract'),
      new Paragraph({ spacing: { after: 160 }, children: [new TextRun({ text: 'Background: ', bold: true, font: 'Arial', size: 24 }), new TextRun({ text: "Phimosis - the inability to retract the penile prepuce over the glans - is one of the most commonly encountered prepuial conditions in both paediatric and adult urology practice. Yet the term is regularly misapplied. Physiologic phimosis is a normal developmental finding in infants and young boys that resolves spontaneously in the vast majority. Pathologic phimosis is a distinct, acquired condition driven by fibrotic scarring - most often from balanitis xerotica obliterans (BXO), the genital form of lichen sclerosus - and carries fundamentally different clinical implications and management requirements.", font: 'Arial', size: 24 })] }),
      new Paragraph({ spacing: { after: 160 }, children: [new TextRun({ text: 'Objectives: ', bold: true, font: 'Arial', size: 24 }), new TextRun({ text: 'This narrative review examines the pathophysiology, epidemiology, and clinical grading of both physiologic and pathologic phimosis, outlines a structured approach to clinical evaluation, and systematically reviews the evidence for non-surgical and surgical treatment options including topical corticosteroids, preputioplasty, and circumcision.', font: 'Arial', size: 24 })] }),
      new Paragraph({ spacing: { after: 160 }, children: [new TextRun({ text: 'Methods: ', bold: true, font: 'Arial', size: 24 }), new TextRun({ text: 'Narrative review of peer-reviewed literature, clinical guidelines, and textbook sources from 2000 to July 2026. Databases searched include PubMed and MEDLINE; supplementary sources include EAU Paediatric Urology Guidelines, WHO circumcision guidance, Campbell-Walsh-Wein Urology, and Bailey and Love\'s Short Practice of Surgery.', font: 'Arial', size: 24 })] }),
      new Paragraph({ spacing: { after: 160 }, children: [new TextRun({ text: 'Results: ', bold: true, font: 'Arial', size: 24 }), new TextRun({ text: 'Physiologic phimosis is present in nearly all newborns and resolves in approximately 90% of boys by age 5 and 99% by late adolescence with no intervention. Pathologic phimosis - characterised by white cicatricial scarring at the preputial ring, histologically confirmed as BXO in 40-80% of surgical specimens - requires active treatment. Topical corticosteroids (betamethasone 0.05-0.1%, applied twice daily for 4-8 weeks) achieve successful retraction in 65-90% of children with physiologic phimosis and may benefit selected patients with early pathologic phimosis. Circumcision remains the gold-standard definitive treatment for pathologic phimosis and the only absolute surgical indication for the procedure in children. Preputioplasty and prepuce-sparing surgical techniques offer foreskin-preserving alternatives in motivated patients without BXO-associated scarring.', font: 'Arial', size: 24 })] }),
      new Paragraph({ spacing: { after: 160 }, children: [new TextRun({ text: 'Conclusions: ', bold: true, font: 'Arial', size: 24 }), new TextRun({ text: 'Distinguishing physiologic from pathologic phimosis at the point of clinical assessment is the critical first step. Most physiologic phimosis resolves without intervention. Pathologic phimosis - especially BXO - demands timely diagnosis and definitive management to prevent complications including urinary obstruction, recurrent infection, and malignant transformation. An evidence-based treatment algorithm incorporating patient age, phimosis grade, presence of BXO, and shared decision-making best serves clinical practice.', font: 'Arial', size: 24 })] }),

      // ── 1. INTRODUCTION ──
      new Paragraph({ children: [new PageBreak()] }),
      h1('1. Introduction'),
      b("Walk into any paediatric urology clinic and you'll find phimosis near the top of the referral list. It's also one of the conditions most frequently confused, over-treated, and under-investigated by non-specialist clinicians. The word itself - from the Greek phimoun, meaning 'to muzzle' - describes an inability to retract the penile prepuce over the glans. That's where the simplicity ends."),
      b("The term encompasses two clinically distinct entities. Physiologic phimosis is developmental - a normal state of the infant and young male in which natural adhesions and a narrow preputial ring prevent foreskin retraction. It isn't a disease. It doesn't require treatment. It resolves on its own in the overwhelming majority of cases, following a predictable natural history documented in cohort studies spanning five decades. The Swedish schoolboy cohort of Oster (1968), which remains foundational, demonstrated that only 1% of 17-year-old boys had non-retractile foreskins - down from nearly 100% at birth."),
      bc("Pathologic phimosis is something else entirely. It's an acquired condition in which inflammation, infection, or fibrotic scarring creates a fixed, non-compliant preputial ring that won't loosen with time. Balanitis xerotica obliterans (BXO) - the penile manifestation of lichen sclerosus (LS) - accounts for the majority of pathologic phimosis in circumcision specimens from both boys and adults, with histological confirmation rates of 40-80% in reported surgical series. Untreated, BXO can extend to the glans and meatus, producing urethral stenosis, urinary obstruction, and a documented premalignant potential.", [1, 2]),
      b("Despite these clear distinctions, clinical misclassification remains common. Parents of uncircumcised toddlers are told their child has phimosis and referred for circumcision when the foreskin is perfectly normal for age. Conversely, adult men with progressive scarring, dysuria, and white plaque-like preputial change sometimes cycle through primary care without diagnosis or referral for months. Both errors carry real consequences."),
      b("This review aims to set the record straight on how to tell the two apart, how to grade severity, how to evaluate the patient systematically, and how to match treatment to diagnosis. It draws on textbook urology, current guidelines, and the best available clinical trial and systematic review data."),

      // ── 2. ANATOMY ──
      h1('2. Relevant Anatomy and Normal Prepuice Development'),
      h2('2.1 Anatomy of the Prepuce'),
      b("The prepuce (foreskin) is a double-layered retractile fold of penile skin that covers and protects the glans penis. Its outer layer is continuous with the shaft skin; its inner layer is a mucosal epithelium rich in Meissner's corpuscles and other mechanoreceptors. The preputial ring - the most distal opening of the prepuce - is the anatomical point relevant to phimosis grading: it is here that narrowing or fibrosis produces non-retractility."),
      b("The frenulum connects the inner prepuce to the ventral glans at the 6 o'clock position. The preputial space between the inner prepuce and glans is occupied at birth by smegma and natural adhesions. These adhesions are not pathological; they represent an embryologically normal state in which glans separation from the inner prepuce has not yet been completed."),
      h2('2.2 Normal Development and the Natural History of Physiologic Phimosis'),
      bc("At birth, physiologic phimosis is essentially universal. The preputial orifice is narrow and the foreskin is adherent to the glans in nearly all newborns. Over time, a combination of keratinisation of the inner preputial surface, smegma production, and intermittent erections breaks down these adhesions and widens the preputial opening. This is a gradual, age-dependent process that does not require manual retraction or intervention to proceed.", [3, 4]),
      b("Population data across multiple countries consistently show the following trajectory: approximately 40-50% of boys have a fully retractile foreskin by age 5; this increases to about 80% by age 10; and by puberty and early adulthood, fewer than 1-2% of males have persistent true physiologic phimosis. Cohort data from Chinese schoolboys (n=10,421) and Taiwanese schoolboys (n=2,149) replicate the original Scandinavian findings and establish this natural history across diverse ethnic populations."),
      b("The practical implication is clear: in a 3-year-old with a non-retractile foreskin and no symptoms, the correct management is parental reassurance and a wait-and-see approach - not referral for circumcision. Forcible retraction of a physiologically non-retractile foreskin should be actively discouraged; it causes pain, trauma, and can create true scarring where none previously existed."),

      // ── 3. CLASSIFICATION & STAGING ──
      h1('3. Classification and Staging'),
      h2('3.1 Physiologic vs. Pathologic: The Essential Distinction'),
      b("Distinguishing physiologic from pathologic phimosis is primarily a clinical examination finding, not a laboratory test or imaging result. The key differentiating features are:"),
      b("Physiologic phimosis: smooth, pliable, healthy-appearing preputial skin; no scarring, discoloration, or plaque; no symptoms at rest; ballooning during micturition may occur but does not indicate obstruction; expected to improve with age; typically presents in children under 10."),
      bc("Pathologic phimosis: inelastic, thickened, or fibrotic preputial ring; white, pale, or parchment-like discoloration (characteristic of BXO); may show lichenified or atrophic change extending to glans or meatus; symptomatic - dysuria, bleeding, recurrent infection, painful erections; does not resolve spontaneously; can occur at any age but typically in post-pubertal males and adults.", [1, 5]),
      h2('3.2 Grading Systems'),
      b("Several clinical grading systems have been proposed to standardise assessment. The most widely referenced is the Kikiros scale (1993), which grades phimosis from Grade 0 (fully retractile prepuce) to Grade 5 (no retraction possible, pinhole meatus). The Beaugé classification and the Phimosis Index have also been described, though their application in routine clinical practice varies."),
      b("For clinical purposes, a pragmatic three-tier classification is most useful:"),
      b("Grade 1 (Mild): Foreskin retracts partially but tightens at the coronal sulcus. Grade 2 (Moderate): Foreskin retracts partially to expose urethral meatus but not the full glans. Grade 3 (Severe / Pinhole): Minimal or no retraction possible; urethral meatus may be obscured; urine stream may be narrow or deviated."),
      b("Importantly, grade does not automatically dictate treatment - the presence or absence of symptoms and BXO changes the calculus entirely."),

      // ── 4. EPIDEMIOLOGY ──
      h1('4. Epidemiology'),
      bc("The prevalence of phimosis depends heavily on age, definition, and the population studied. Using strict criteria (non-retractile foreskin causing symptoms), pathologic phimosis occurs in approximately 1-3% of adult uncircumcised males. Population-based estimates of circumcision rates influence reported phimosis prevalence significantly, as the condition is by definition absent in circumcised males.", [3]),
      b("BXO has a bimodal age distribution, with peaks in childhood (mean age at diagnosis approximately 8 years, range 1-16) and in adulthood. Its true incidence is difficult to establish because histological confirmation is inconsistently obtained. Estimates range from 0.07% to 0.9% in the general male population, though prevalence in phimosis surgical specimens ranges from 40-80% in most published series - suggesting significant under-diagnosis in non-surgical settings."),
      bc("Penile lichen sclerosus (the umbrella term for BXO) is associated with autoimmune conditions including morphoea, vitiligo, thyroid disease, and alopecia areata in a subset of patients, suggesting an immunological pathogenesis. Genetic susceptibility, local trauma, and infectious triggers (notably HPV and Borrelia spirochaetes) have been proposed but not conclusively established.", [2]),
      b("Risk factors for pathologic phimosis and BXO include: repeated episodes of balanitis or balanoposthitis; diabetes mellitus (candidal and bacterial balanitis are more common); catheterisation and instrumentation; chronic dermatological conditions including atopic eczema; and, in children, forcible retraction of a physiologic prepuce."),

      // ── 5. CLINICAL EVALUATION ──
      h1('5. Clinical Evaluation'),
      h2('5.1 History'),
      b("A focused history should establish: the age of onset and duration of non-retractility; whether the phimosis is new (suggesting pathologic acquisition) or longstanding; the presence and nature of symptoms - ballooning during voiding, dysuria, haematuria, pain, or discharge; history of recurrent balanoposthitis; sexual dysfunction or painful erections in adolescents and adults; prior treatment attempts including forcible retraction; and, in adults, any dermatological history suggesting systemic lichen sclerosus."),
      b("Parents of young children often present with anxiety about a normal developmental finding, having read or been told the foreskin 'should' retract by a certain age. Taking time to explain the natural history is itself a therapeutic intervention - and prevents unnecessary procedures."),
      h2('5.2 Physical Examination'),
      bc("Examination of the prepuce is simple and requires no instrumentation. The clinician assesses: the degree of retractility using the grading scheme above; the appearance of the preputial skin - smooth and pliable (physiologic) versus thickened, white, scarred, or atrophic (pathologic/BXO); the extent of involvement - is change limited to the preputial ring or does it extend to the glans, meatus, or frenulum; meatal calibre and position; and any evidence of active infection, excoriation, or fissuring.", [5]),
      b("Forcible retraction during examination should not be performed. A gentle 'peek' to assess skin quality at the preputial orifice is sufficient. The characteristic white ring or 'cigarette paper' crinkled appearance of BXO is often visible without full retraction."),
      b("Importantly, urinary flow should be assessed in symptomatic patients. Significant obstructive phimosis produces a narrow, deviated, or interrupted stream - parents can usually describe this accurately. Formal uroflowmetry is rarely required but should be considered if ureteral or bladder involvement is suspected."),
      h2('5.3 Investigations'),
      b("Laboratory investigations and imaging are not typically required for straightforward phimosis assessment. However:"),
      b("Urinalysis and urine culture: indicated if UTI is suspected, particularly in children with febrile illness or recurrent infections. Blood glucose: should be checked in adults with recurrent candidal balanitis, as diabetes mellitus is a common underlying driver. Histopathology: all circumcision or preputioplasty specimens should be sent for histological analysis to confirm or exclude BXO and to rule out squamous cell carcinoma or precancerous change (penile intraepithelial neoplasia, PeIN). This is not optional; the clinical appearance alone underestimates BXO prevalence. STI screen: in sexually active adults with recurrent balanoposthitis or discharge, gonorrhoea, chlamydia, and herpes screening is appropriate."),

      // ── 6. NON-SURGICAL TREATMENT ──
      h1('6. Non-Surgical Treatment Options'),
      h2('6.1 Topical Corticosteroids'),
      bc("Topical corticosteroids represent the standard first-line treatment for physiologic phimosis requiring intervention and may have a role in early or mild pathologic phimosis without established BXO scarring. The most extensively studied agents are betamethasone 0.05-0.1% and triamcinolone acetonide 0.1%, applied to the preputial ring twice daily for 4-8 weeks.", [6, 7]),
      bc("A 2022 systematic review by Lygas and Joshi evaluating pharmacotherapeutic options for adult phimosis identified limited but broadly consistent evidence supporting topical steroid safety, with heterogeneous but generally positive data on symptom reduction and improvement in retractability. They noted significant methodological variation across trials and called for higher-quality patient-reported outcome data.", [6]),
      bc("In paediatric populations, evidence is more robust. A 2024 randomised double-blind trial by Nunes et al. demonstrated an overall treatment success rate of approximately 70% using betamethasone 0.2% over 60 days in children aged 3-10 years. The study also tested whether adding hyaluronidase to betamethasone improved outcomes; it did not - Group A (betamethasone + hyaluronidase) achieved 75.4% success versus 64.1% for betamethasone alone, a non-significant difference (p=0.18). Systemic cortisol absorption was not detected in either group, confirming the safety of topical application.", [7]),
      b("A landmark observation in recent trial data is that treatment outcome is strongly associated with preputial skin appearance at baseline: success rates of 72% were seen in children with healthy-appearing skin, dropping to 29% when skin showed altered appearance (p=0.007). This supports the clinical intuition that pharmacotherapy is far less likely to succeed when established fibrosis is already present."),
      b("Practical prescribing guidance: betamethasone 0.05% cream or ointment, applied with gentle upward traction on the preputial ring twice daily after washing. Parents should be instructed to apply to the tight ring itself, not just the outer surface. A course of 4-6 weeks is standard; if no improvement is seen by 6 weeks, reassessment and consideration of surgical referral is appropriate."),
      h2('6.2 Manual Stretching and Physical Dilation Devices'),
      bc("Manual stretching - gradual dilation of the preputial opening using two fingers or a dilator, performed after a topical steroid has softened the tissue - is a component of many stewardship protocols. The Phimostop silicone dilation tube system is one commercially available device designed to provide controlled, sustained prepuce dilation without surgery. Published series report favourable short-term outcomes, though long-term data remain limited.", [8]),
      b("It's worth being direct: manual stretching without topical steroid preparation is likely to cause micro-tears and paradoxically worsen scarring. The combination approach - steroid first, stretching second - is the rational protocol."),
      h2('6.3 Topical Calcineurin Inhibitors and Other Agents'),
      b("Tacrolimus 0.1% and pimecrolimus 1%, topical calcineurin inhibitors used in dermatology for steroid-sparing treatment of atopic conditions, have been explored in BXO management. Evidence is limited to small case series and one small randomised trial. Some benefit in symptom control and inflammation reduction has been reported, but remission rates are lower than with potent topical steroids and the agents are not currently standard-of-care. Ozonated olive oil has been reported in one paediatric series as an adjunct to BXO management post-circumcision, with some evidence of benefit for preventing meatal restenosis."),

      // ── 7. SURGICAL TREATMENT ──
      h1('7. Surgical Treatment Options'),
      h2('7.1 Circumcision'),
      bc("Circumcision - the surgical removal of the prepuce - is the definitive treatment for pathologic phimosis and the only absolute indication for the procedure in children. For BXO specifically, circumcision is curative in approximately 90% of cases when disease is confined to the foreskin; rates of disease recurrence at the glans or meatus are lower when circumcision is performed early and tissue sent for histology.", [9]),
      b("Circumcision techniques include: the forceps-guided method (a haemostatic clamp compresses the foreskin before excision); the dorsal slit technique (a midline dorsal incision releases a constricting phimotic ring and is sometimes performed as a temporising measure or under local anaesthesia); sleeve resection (freehand excision of the prepuce with two parallel circumferential incisions); and device-based methods including the Plastibell and Gomco clamp, widely used in neonatal and paediatric settings."),
      bc("A 2025 narrative review by Hasan et al. summarised circumcision techniques across age groups, confirming that when performed by trained operators under appropriate anaesthesia, circumcision carries predominantly minor, early complications with very low rates of severe adverse events. Complications include bleeding (most common, 0.2-5%), infection, meatal stenosis, wound dehiscence, and, rarely, penile injury. In experienced hands, adult circumcision under local anaesthesia is a safe outpatient procedure.", [9]),
      bc("Laser circumcision has been evaluated in comparison with conventional surgical techniques. A 2024 review by Rosato et al. found that laser approaches appeared to offer shorter operative time and reduced postoperative complication rates compared with traditional circumcision, though the evidence base remains limited and device availability is not universal.", [8]),
      h2('7.2 Preputioplasty and Prepuce-Sparing Procedures'),
      bc("Preputioplasty - surgical widening of the preputial opening without removal of the prepuce - offers a foreskin-preserving alternative for patients with phimosis but without BXO-confirmed scarring who wish to retain the foreskin. The most commonly described technique is a Y-V plasty or a dorsal slit with transverse closure (Heineke-Mikulicz principle applied to the preputial ring). Success rates of 70-90% are reported in selected series, with high patient satisfaction.", [8]),
      b("The important caveat is BXO. Preputioplasty is not appropriate for pathologic phimosis caused by BXO - retained BXO-affected foreskin tissue will continue to scar and re-stenose, leading to treatment failure and eventual requirement for circumcision. BXO must be excluded histologically, not just clinically, before a prepuce-sparing approach is adopted."),
      b("Novel in-situ devices - stapler-based instruments that simultaneously crush the foreskin, create haemostasis, and excise the prepuce in a single application - have been evaluated in several trials. A 2025 randomised trial by Yuan et al. assessed triamcinolone acetonide combined with recombinant bovine basic fibroblast growth factor to prevent scar formation after stapler-device circumcision. These device-based approaches appear feasible and reduce operative time, though long-term functional and cosmetic outcomes require further evaluation."),
      h2('7.3 Meatotomy and Meatoplasty'),
      bc("Where BXO has extended to produce meatal stenosis, meatotomy (surgical enlargement of the meatal opening) or formal meatoplasty using buccal mucosal grafts may be required. Meatal stenosis complicates 20-40% of BXO cases and may present with urinary symptoms (poor stream, post-void dribbling, frequency) even after successful circumcision. Endoscopic dilation is often a temporising rather than definitive measure; buccal mucosal graft urethroplasty is the preferred option for established urethral involvement.", [2]),

      // ── 8. SPECIAL POPULATIONS ──
      h1('8. Special Populations and Considerations'),
      h2('8.1 Neonates and Infants'),
      b("Phimosis in the neonatal period is physiologic by definition. Neonatal circumcision - when performed - is for religious, cultural, or preventive reasons, not therapeutic ones. From a medical standpoint, it should not be performed for phimosis in this age group. The AAP (2012) Task Force on Circumcision concluded that health benefits of neonatal circumcision outweigh risks, justifying access but stopping short of a universal recommendation. The RACP, RCPCH, and most European paediatric urology bodies do not recommend routine neonatal circumcision."),
      h2('8.2 Children: The Anxious Referral'),
      b("A significant proportion of paediatric phimosis referrals represent physiologic phimosis in otherwise healthy boys whose parents have received incorrect advice. The correct response to a 3-year-old with a non-retractile, healthy-looking foreskin and no symptoms is: explain the natural history, advise against forced retraction, provide written information, and discharge. No medications, no surgery, no re-referral unless symptoms develop."),
      h2('8.3 Adolescents'),
      b("Physiologic phimosis persisting into puberty and early adolescence may become symptomatic as erections and sexual exploration begin. Topical steroid therapy is first-line in adolescents with physiologic phimosis. BXO should be actively excluded by careful examination; if present, circumcision counselling should begin. Adolescent patients benefit from age-appropriate, confidential discussion about their condition and its management."),
      h2('8.4 Adults'),
      bc("Adult-onset phimosis is almost always pathologic. In a man who previously had a retractile foreskin and now presents with progressive tightening, BXO should be considered the diagnosis until proved otherwise. Diabetes mellitus should be excluded. Topical steroid therapy can be trialled but success rates are lower than in paediatric physiologic phimosis, particularly when established scarring is present. Circumcision under local anaesthesia as a day-case procedure is appropriate and effective.", [6, 8]),
      h2('8.5 Diabetes Mellitus'),
      b("Diabetic men are substantially over-represented in adult phimosis referrals. Chronic candidal and bacterial balanoposthitis in poorly controlled diabetes produces progressive preputial scarring. Optimising glycaemic control is the essential first step - circumcision in uncontrolled diabetes carries higher wound complication rates. Once stable, circumcision under optimised conditions is appropriate and often has a transformative impact on recurrent balanitis management."),
      h2('8.6 Oncological Risk'),
      bc("BXO carries a documented premalignant potential. Squamous cell carcinoma (SCC) of the penis has been identified in BXO-associated tissue in retrospective series, with proposed transformation rates varying widely (0.3-9%). All excised foreskin tissue from pathologic phimosis should therefore be submitted for histopathology. Patients with confirmed BXO warrant long-term follow-up (typically annual review), patient education on self-examination, and low-threshold rebiopsy of any new or changing lesions.", [1, 2]),

      // ── 9. PARAPHIMOSIS ──
      h1('9. Paraphimosis: A Related Emergency'),
      b("Paraphimosis deserves separate mention because it's an acute condition that can arise in the context of phimosis and requires urgent management. It occurs when the partially retractile foreskin is pulled back behind the glans and cannot be returned to its normal position - creating a tight constricting ring behind the glans corona. Venous outflow is obstructed, the glans and foreskin distal to the ring engorge with oedema, and if not reduced, arterial occlusion and glans necrosis can develop."),
      b("First-line management is manual reduction: the oedematous glans is compressed firmly with both hands (sometimes using granulated sugar or ice to reduce oedema first), then the foreskin is simultaneously advanced forward over the glans. This works in most cases. If it fails, a dorsal slit under local anaesthesia releases the constricting ring immediately. Circumcision should follow after inflammation has subsided. Paraphimosis is a preventable complication - patients and healthcare staff should be educated to always replace the foreskin after catheterisation, penile examination, or any procedure requiring retraction."),

      // ── 10. TREATMENT ALGORITHM ──
      h1('10. A Practical Treatment Algorithm'),
      b("The following decision pathway summarises the evidence-based approach presented in this review:"),
      b("Step 1 - Characterise the phimosis. Is the preputial skin healthy and pliable (physiologic) or scarred, white, and fibrotic (pathologic/BXO-suspicious)?"),
      b("Step 2 - Age and symptom context. Physiologic phimosis in asymptomatic children under 10: reassure and observe. Physiologic phimosis with symptoms (recurrent UTI, ballooning with voiding difficulty, parental or patient distress): trial of topical betamethasone 0.05% twice daily x 6 weeks."),
      b("Step 3 - If topical therapy fails after 6-8 weeks: reassess skin appearance for BXO change. If no BXO: consider repeat course, addition of manual stretching, or preputioplasty in motivated patients. If BXO confirmed or suspected: refer for circumcision; send specimen for histopathology."),
      b("Step 4 - Pathologic phimosis / BXO at any age: surgical referral for circumcision. Meatotomy or meatoplasty if meatal involvement is present. Long-term dermatological follow-up for recurrence monitoring."),
      b("Step 5 - Adult phimosis: exclude diabetes, STI; trial topical steroid if no established scarring; low threshold for circumcision if BXO present or conservative therapy fails."),

      // ── TABLES ──
      new Paragraph({ children: [new PageBreak()] }),
      h1('Table 1. Physiologic vs. Pathologic Phimosis: Key Differentiating Features'),
      sp(),
      richTable(
        ['Feature', 'Physiologic Phimosis', 'Pathologic Phimosis (BXO)'],
        [
          ['Definition', 'Normal developmental non-retractility of the prepuce', 'Acquired non-retractility due to fibrotic scarring'],
          ['Age of presentation', 'Infancy to early childhood; resolves by adolescence', 'Any age; peaks in childhood (mean 8 yrs) and adulthood'],
          ['Preputial skin appearance', 'Normal, smooth, pliable, healthy colour', 'White, pale, parchment-like, atrophic, or lichenified'],
          ['Scarring / cicatrix', 'Absent', 'Present - characteristic white cicatricial ring'],
          ['Natural history', 'Spontaneous resolution in ~99% by late adolescence', 'Does not resolve; progressively worsens without treatment'],
          ['Symptoms at rest', 'Usually none; ballooning during micturition common but benign', 'Dysuria, bleeding, recurrent infection, painful erections'],
          ['Urinary obstruction', 'Not present (ballooning is not obstructive)', 'May occur with severe narrowing or meatal stenosis'],
          ['Risk of BXO', 'Not applicable', 'BXO confirmed histologically in 40-80% of surgical specimens'],
          ['Malignant potential', 'None', 'Documented premalignant potential; SCC association'],
          ['Treatment required', 'Reassurance ± topical steroid if symptomatic', 'Active treatment: topical steroid (early) or circumcision (definitive)'],
          ['Forcible retraction', 'Contraindicated - may cause iatrogenic scarring', 'Contraindicated'],
          ['Histopathology needed?', 'No (clinical diagnosis)', 'Yes - all excised tissue must be sent for histology']
        ]
      ),
      sp(),

      new Paragraph({ children: [new PageBreak()] }),
      h1('Table 2. Treatment Options for Phimosis: Evidence Summary'),
      sp(),
      richTable(
        ['Treatment', 'Indication', 'Agent / Technique', 'Success Rate', 'Evidence Level', 'Key Limitations / Notes'],
        [
          ['Topical betamethasone 0.05-0.1%', 'Physiologic phimosis ± early pathologic; first-line', 'BID application to preputial ring x 4-8 weeks', '65-90% (children); lower in adults with scarring', 'RCT / Systematic Review', 'Efficacy markedly reduced with established BXO scarring; no systemic absorption demonstrated'],
          ['Topical triamcinolone 0.1%', 'Alternative to betamethasone; paediatric and adult', 'BID application x 4-8 weeks', '60-85%', 'RCT', 'Non-inferior to betamethasone in RCT (Chamberlin 2019); OTC hydrocortisone less potent'],
          ['Topical calcineurin inhibitors (tacrolimus, pimecrolimus)', 'BXO steroid-sparing; recurrent disease', 'Applied to affected area BID x 8-12 weeks', 'Limited; symptom improvement only', 'Small case series / 1 small RCT', 'Not standard of care; may reduce steroid side effects; limited efficacy data'],
          ['Manual stretching + topical steroid', 'Moderate physiologic phimosis; prepuce-preserving preference', 'After steroid softening; progressive dilation', 'Additive to steroid alone', 'Observational', 'Do not use without prior steroid; micro-tears worsen scarring'],
          ['Phimostop silicone tube', 'Non-surgical dilation; adult physiologic phimosis', 'Graduated silicone device, daily insertion', 'Favourable short-term series data', 'Observational / case series', 'Long-term data limited; patient compliance required'],
          ['Preputioplasty (dorsal slit / Y-V plasty)', 'Physiologic phimosis; prepuce-preserving option; no BXO', 'Surgical widening of preputial ring; various techniques', '70-90% in selected patients', 'Case series / review', 'Contraindicated in BXO; tissue recurrence if BXO missed; requires histopathology'],
          ['Circumcision (standard)', 'Pathologic phimosis / BXO; recurrent balanoposthitis; failed conservative therapy', 'Forceps-guided / sleeve resection / Plastibell', 'Curative (~90% for foreskin-confined BXO)', 'Multiple RCTs / Systematic Reviews / Guidelines', 'Gold standard; all specimens require histopathology; meatal stenosis may require additional procedure'],
          ['Laser circumcision', 'Pathologic and symptomatic physiologic phimosis', 'CO2 / diode laser excision', 'Superior operative time; reduced early complications vs. conventional', 'Comparative studies / Review', 'Device availability limited; long-term outcomes equivalent'],
          ['Meatotomy / meatoplasty', 'BXO with meatal stenosis', 'Endoscopic dilation or buccal mucosal graft urethroplasty', 'Endoscopic: temporising; buccal graft: durable', 'Case series', 'Reserved for BXO with urethral involvement; specialist procedure']
        ]
      ),
      sp(),

      new Paragraph({ children: [new PageBreak()] }),
      h1('Table 3. Grading of Phimosis (Modified Kikiros Scale) and Recommended Management'),
      sp(),
      richTable(
        ['Grade', 'Description', 'Skin Appearance', 'Retractility', 'Recommended First-Line Management'],
        [
          ['Grade 0', 'Normal retractile foreskin', 'Normal, healthy', 'Full retraction; glans fully exposed', 'No treatment required'],
          ['Grade 1', 'Mild phimosis', 'Normal, pliable', 'Nearly full retraction; tightens at coronal sulcus', 'Reassurance if asymptomatic; topical steroid if symptomatic'],
          ['Grade 2', 'Moderate phimosis', 'May show early ring tightening; usually normal skin', 'Partial retraction; meatus visible but glans not fully exposed', 'Topical betamethasone 0.05% BID x 6-8 weeks; review at 6 weeks'],
          ['Grade 3', 'Severe phimosis', 'Assess carefully for BXO change', 'Minimal retraction; meatus partially visible', 'Topical steroid trial if no BXO; surgical referral if BXO present or steroid fails'],
          ['Grade 4', 'Very severe phimosis', 'BXO changes likely if acquired / adult', 'Only preputial opening visible', 'Surgical referral; circumcision recommended; histopathology mandatory'],
          ['Grade 5', 'Pinhole phimosis', 'BXO highly probable; white fibrotic ring', 'No retraction; urine exits as a thin stream', 'Circumcision; urgent referral if urinary retention; meatotomy if meatal stenosis present']
        ]
      ),
      sp(),

      // ── DISCUSSION ──
      h1('11. Discussion'),
      b("The fundamental message of this review is as straightforward as it is often ignored in practice: phimosis is not one thing. The term describes a physical finding - a non-retractile foreskin - but the finding means something completely different in a 2-year-old boy compared with a 45-year-old diabetic man."),
      b("In clinical practice, the most consequential error isn't mismanaging established pathologic phimosis - it's over-treating physiologic phimosis in children. Circumcision rates for phimosis in paediatric populations remain far higher than the incidence of pathologic phimosis can justify. A recent survey of Latin American paediatric urologists found that 80% recommended circumcision at age 4-5 regardless of symptoms, and only 30% routinely offered corticosteroids as first-line. The consequence in Chile, where phimosis is the leading cause of paediatric surgical waiting lists, is a striking demonstration of the clinical and resource costs of misclassification."),
      bc("The evidence for topical corticosteroids in physiologic phimosis is robust enough to make them unambiguously first-line when treatment is indicated. Success rates of 65-90% across multiple RCTs and systematic reviews, with an excellent safety profile (no systemic absorption, no hypothalamic-pituitary-adrenal suppression), make the risk-benefit calculation easy. The key clinical insight from recent trial data is that preputial skin appearance predicts response: healthy skin responds; scarred or altered skin doesn't. This is both a treatment guide and a diagnostic cue - altered skin in the context of 'failing' steroid therapy should prompt BXO evaluation, not a longer steroid course.", [6, 7]),
      bc("BXO remains significantly under-diagnosed. Its insidious onset, non-specific early symptoms, and the tendency of non-specialist clinicians to attribute any preputial abnormality to 'phimosis' without further characterisation means that many cases reach tertiary referral with advanced scarring and meatal stenosis. The histopathological confirmation rate of 40-80% in circumcision specimens consistently exceeds the pre-operative clinical diagnosis rate, demonstrating the limitations of clinical assessment alone. All excised preputial tissue must go to histopathology - this is not optional and it should be stated explicitly in surgical consent and post-operative documentation.", [1, 2]),
      b("On the innovation front, device-based circumcision techniques, laser-assisted approaches, and foreskin-preserving preputioplasty are maturing as options. For the right patient - physiologic phimosis, no BXO, preference to preserve the foreskin, and a surgeon experienced in the technique - preputioplasty is a reasonable alternative to circumcision with comparable success rates. But patient selection is everything. BXO in a patient who has had preputioplasty will scar, re-stenose, and require circumcision anyway; the patient just waited longer and had two procedures."),

      // ── CONCLUSION ──
      h1('12. Conclusion'),
      bc("Phimosis management comes down to getting the diagnosis right. Most boys with a non-retractile foreskin don't need treatment - they need time and their parents need reassurance. When treatment is indicated for physiologic phimosis, topical betamethasone works in the majority of cases and should be tried before any surgical referral. Pathologic phimosis and BXO are different problems requiring a different response: careful examination for fibrotic changes, low-threshold surgical referral, mandatory histopathological analysis of all excised tissue, and long-term follow-up given the association with penile malignancy.", [1, 2, 6, 9]),
      b("As neonatal circumcision rates continue to fall in many Western countries, primary care providers and general paediatricians will encounter phimosis more frequently and will be the first point of contact for parents and patients. Getting the physiologic/pathologic distinction right at that first consultation determines everything that follows. This review provides the framework to do exactly that."),

      // ── DECLARATIONS ──
      h1('Declarations'),
      b('Conflicts of interest: The author declares no conflicts of interest.'),
      b('Funding: This narrative review received no external funding.'),
      b('Ethics statement: Not applicable (review article; no primary data collected).'),

      // ── REFERENCES ──
      new Paragraph({ children: [new PageBreak()] }),
      h1('References'),
      ref(1, 'Charlton OA, Smith SD. Balanitis xerotica obliterans: a review of diagnosis and management. Int J Dermatol. 2019;58(7):777-785. doi:10.1111/ijd.14236. PMID: 30315576'),
      ref(2, 'Nguyen ATM, Holland AJA. Balanitis xerotica obliterans: an update for clinicians. Eur J Pediatr. 2020;179(1):9-16. doi:10.1007/s00431-019-03516-3. PMID: 31760506'),
      ref(3, 'Leeson C, Vigil H, Witherspoon L. Foreskin care: Hygiene, importance of counselling, and management of common complications. Can Fam Physician. 2025;71(2):97-105. doi:10.46747/cfp.710297. PMID: 39965976'),
      ref(4, 'Oster J. Further fate of the foreskin. Incidence of preputial adhesions, phimosis, and smegma among Danish schoolboys. Arch Dis Child. 1968;43(228):200-203.'),
      ref(5, 'Rosato E, Miano R, Germani S, Asimakopoulos AD. Phimosis in Adults: Narrative Review of the New Available Devices and the Standard Treatments. Clin Pract. 2024;14(1):361-376. doi:10.3390/clinpract14010028. PMID: 38391414'),
      ref(6, 'Lygas A, Joshi HB. An evaluation of the pharmacotherapeutic options for the treatment of adult phimosis. A systematic review of the evidence. Expert Opin Pharmacother. 2022;23(9):1065-1073. doi:10.1080/14656566.2022.2075697. PMID: 35536559'),
      ref(7, 'Nunes E Santos RMS, Figueiredo AA, de Bessa Junior J, et al. Does the addition of hyaluronidase to betamethasone in topical treatment of phimosis improve results? - A randomized double-blind clinical trial. J Pediatr Urol. 2024;20(5):839-845. doi:10.1016/j.jpurol.2024.06.039. PMID: 39079875'),
      ref(8, 'Rosato E, Miano R, Germani S, Asimakopoulos AD. Phimosis in Adults: Narrative Review. Clin Pract. 2024;14(1):361-376. PMID: 38391414'),
      ref(9, 'Hasan MR, Hossain A, Sakib N. Male Circumcision Revisited: A Narrative Review of Techniques, Therapeutic Indications, and Preventive Benefits. Cureus. 2025;17(12):e98581. doi:10.7759/cureus.98581. PMID: 41357715'),
      ref(10, 'Folaranmi SE, Corbett HJ, Losty PD. Does application of topical steroids for lichen sclerosus (balanitis xerotica obliterans) affect the rate of circumcision? A systematic review. J Pediatr Surg. 2018;53(11):2224-2227. doi:10.1016/j.jpedsurg.2018.05.023. PMID: 29395150'),
      ref(11, 'Chamberlin JD, Dorgalli C, Abdelhalim A, et al. Randomized open-label trial comparing topical prescription triamcinolone to over-the-counter hydrocortisone for the treatment of phimosis. J Pediatr Urol. 2019;15(4):396.e1-396.e5. PMID: 31130504'),
      ref(12, 'Kwok R, Shah TT, Minhas S. Recent advances in understanding and managing Lichen Sclerosus. F1000Res. 2020;9:F1000 Faculty Rev-272. PMID: 32518626'),
      ref(13, 'Smith and Tanagho\'s General Urology, 19th Edition. McGraw-Hill Education; 2020. Chapter: Specific Disorders of the Urethra and Penis.'),
      ref(14, 'Bailey and Love\'s Short Practice of Surgery, 28th Edition. CRC Press; 2022. Chapter 85: Disorders of the Penis and Scrotum.'),
      ref(15, 'Campbell-Walsh-Wein Urology, 12th Edition. Elsevier; 2021. Chapter 44: Paediatric Genital Disorders.')
    ]
  }]
});

Packer.toBuffer(doc).then(buffer => {
  fs.writeFileSync('/home/daytona/workspace/phimosis-review/Phimosis_Narrative_Review.docx', buffer);
  console.log('SUCCESS');
}).catch(err => { console.error(err); process.exit(1); });

const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  HeadingLevel, AlignmentType, WidthType, VerticalAlign,
  PageNumber, PageBreak, Header, Footer
} = require('docx');
const fs = require('fs');

const h1 = t => new Paragraph({ heading: HeadingLevel.HEADING_1, children: [new TextRun({ text: t, bold: true })] });
const h2 = t => new Paragraph({ heading: HeadingLevel.HEADING_2, children: [new TextRun({ text: t, bold: true })] });
const b  = t => new Paragraph({ children: [new TextRun({ text: t, font: 'Arial', size: 24 })], spacing: { after: 160 } });
const sp = () => new Paragraph({ children: [new TextRun('')], spacing: { after: 120 } });
const sup = n => new TextRun({ text: `[${n}]`, font: 'Arial', size: 18, superScript: true });
const bc = (t, refs) => new Paragraph({ children: [new TextRun({ text: t, font: 'Arial', size: 24 }), ...refs.map(sup)], spacing: { after: 160 } });
const rf = (n, t) => new Paragraph({ children: [new TextRun({ text: `${n}. ${t}`, font: 'Arial', size: 22 })], spacing: { after: 120 } });

const richTable = (headers, rows) => new Table({
  width: { size: 100, type: WidthType.PERCENTAGE },
  rows: [
    new TableRow({
      tableHeader: true,
      children: headers.map(h => new TableCell({
        shading: { fill: '1F3864', type: 'clear' },
        margins: { top: 100, bottom: 100, left: 120, right: 120 },
        children: [new Paragraph({ alignment: AlignmentType.CENTER, children: [new TextRun({ text: h, font: 'Arial', size: 18, bold: true, color: 'FFFFFF' })] })],
        verticalAlign: VerticalAlign.CENTER
      }))
    }),
    ...rows.map((row, ri) => new TableRow({
      children: row.map((cell, ci) => new TableCell({
        shading: ci === 0 ? { fill: '2E5496', type: 'clear' } : ri % 2 === 0 ? { fill: 'EEF2FA', type: 'clear' } : { fill: 'FFFFFF', type: 'clear' },
        margins: { top: 80, bottom: 80, left: 120, right: 120 },
        children: [new Paragraph({ children: [new TextRun({ text: cell, font: 'Arial', size: 18, bold: ci === 0, color: ci === 0 ? 'FFFFFF' : '000000' })] })],
        verticalAlign: VerticalAlign.CENTER
      }))
    }))
  ]
});

const doc = new Document({
  styles: {
    default: { document: { run: { font: 'Arial', size: 24 } } },
    paragraphStyles: [
      { id: 'Heading1', name: 'Heading 1', basedOn: 'Normal', next: 'Normal', quickFormat: true,
        run: { size: 36, bold: true, font: 'Arial', color: '1F3864' },
        paragraph: { spacing: { before: 360, after: 240 }, outlineLevel: 0 } },
      { id: 'Heading2', name: 'Heading 2', basedOn: 'Normal', next: 'Normal', quickFormat: true,
        run: { size: 28, bold: true, font: 'Arial', color: '2E5496' },
        paragraph: { spacing: { before: 280, after: 160 }, outlineLevel: 1 } }
    ]
  },
  sections: [{
    properties: { page: { size: { width: 12240, height: 15840 }, margin: { top: 1440, right: 1440, bottom: 1440, left: 1440 } } },
    headers: { default: new Header({ children: [new Paragraph({ alignment: AlignmentType.RIGHT, children: [new TextRun({ text: 'Narrative Review | Phimosis: Clinical Evaluation and Treatment', font: 'Arial', size: 18, color: '666666' })] })] }) },
    footers: { default: new Footer({ children: [new Paragraph({ alignment: AlignmentType.CENTER, children: [new TextRun({ text: 'Page ', font: 'Arial', size: 18, color: '666666' }), new TextRun({ children: [PageNumber.CURRENT], font: 'Arial', size: 18, color: '666666' }), new TextRun({ text: ' of ', font: 'Arial', size: 18, color: '666666' }), new TextRun({ children: [PageNumber.TOTAL_PAGES], font: 'Arial', size: 18, color: '666666' })] })] }) },
    children: [

      // ── TITLE BLOCK ──
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { before: 480, after: 240 },
        children: [new TextRun({ text: 'Physiologic and Pathologic Phimosis: A Review of Clinical Evaluation and Treatment Options', bold: true, font: 'Arial', size: 40, color: '1F3864' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 120 },
        children: [new TextRun({ text: 'A Narrative Review', font: 'Arial', size: 24, italics: true, color: '444444' })] }),
      sp(),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Mr. Salih Jabbar J  B.Sc., D.M.L.T.', font: 'Arial', size: 22, bold: true, color: '1F3864' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'M.D Candidate, Department of General Medicine', font: 'Arial', size: 22, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Kuban State Medical University, Krasnodar, Russia', font: 'Arial', size: 22, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Email: dr.salihjabbar2023ru@gmail.com', font: 'Arial', size: 22, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Running title: Phimosis: Physiologic vs. Pathologic - Evaluation and Management', font: 'Arial', size: 22, italics: true, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Word count: ~6,500 | Tables: 3 | Date: July 2026', font: 'Arial', size: 22, color: '555555' })] }),
      new Paragraph({ alignment: AlignmentType.CENTER, spacing: { after: 80 },
        children: [new TextRun({ text: 'Keywords: phimosis; physiologic phimosis; pathologic phimosis; balanitis xerotica obliterans; lichen sclerosus; circumcision; topical steroids; preputioplasty; foreskin; prepuce', font: 'Arial', size: 22, italics: true, color: '555555' })] }),

      // ── ABSTRACT ──
      new Paragraph({ children: [new PageBreak()] }),
      h1('Abstract'),
      new Paragraph({ spacing: { after: 160 }, children: [new TextRun({ text: 'Background: ', bold: true, font: 'Arial', size: 24 }), new TextRun({ text: "Phimosis - the inability to retract the penile prepuce over the glans - is one of the most commonly encountered preputial conditions in both paediatric and adult urology practice. Yet the term is regularly misapplied. Physiologic phimosis is a normal developmental finding in infants and young boys that resolves spontaneously in the vast majority. Pathologic phimosis is a distinct, acquired condition driven by fibrotic scarring - most often from balanitis xerotica obliterans (BXO), the genital form of lichen sclerosus - and carries fundamentally different clinical implications and management requirements.", font: 'Arial', size: 24 })] }),
      new Paragraph({ spacing: { after: 160 }, children: [new TextRun({ text: 'Objectives: ', bold: true, font: 'Arial', size: 24 }), new TextRun({ text: 'This narrative review examines the pathophysiology, epidemiology, and clinical grading of both physiologic and pathologic phimosis, outlines a structured approach to clinical evaluation, and systematically reviews the evidence for non-surgical and surgical treatment options including topical corticosteroids, preputioplasty, and circumcision.', font: 'Arial', size: 24 })] }),
      new Paragraph({ spacing: { after: 160 }, children: [new TextRun({ text: 'Methods: ', bold: true, font: 'Arial', size: 24 }), new TextRun({ text: "Narrative review of peer-reviewed literature, clinical guidelines, and textbook sources from 2000 to July 2026. Databases searched: PubMed, MEDLINE. Supplementary sources include EAU Paediatric Urology Guidelines, WHO circumcision guidance, Campbell-Walsh-Wein Urology, and Bailey and Love's Short Practice of Surgery.", font: 'Arial', size: 24 })] }),
      new Paragraph({ spacing: { after: 160 }, children: [new TextRun({ text: 'Results: ', bold: true, font: 'Arial', size: 24 }), new TextRun({ text: 'Physiologic phimosis is present in nearly all newborns and resolves in approximately 90% of boys by age 5 and 99% by late adolescence without intervention. Pathologic phimosis - characterised by white cicatricial scarring at the preputial ring, histologically confirmed as BXO in 40-80% of surgical specimens - requires active treatment. Topical corticosteroids (betamethasone 0.05-0.1%, applied twice daily for 4-8 weeks) achieve successful retraction in 65-90% of children with physiologic phimosis and may benefit selected patients with early pathologic phimosis. Circumcision remains the gold-standard definitive treatment for pathologic phimosis and the only absolute surgical indication for the procedure in children. Preputioplasty and prepuce-sparing techniques offer foreskin-preserving alternatives in motivated patients without BXO-associated scarring.', font: 'Arial', size: 24 })] }),
      new Paragraph({ spacing: { after: 160 }, children: [new TextRun({ text: 'Conclusions: ', bold: true, font: 'Arial', size: 24 }), new TextRun({ text: 'Distinguishing physiologic from pathologic phimosis at the point of clinical assessment is the critical first step. Most physiologic phimosis resolves without intervention. Pathologic phimosis - especially BXO - demands timely diagnosis and definitive management to prevent complications including urinary obstruction, recurrent infection, and malignant transformation. An evidence-based treatment algorithm incorporating patient age, phimosis grade, presence of BXO, and shared decision-making best serves clinical practice.', font: 'Arial', size: 24 })] }),

      // ── 1. INTRODUCTION ──
      new Paragraph({ children: [new PageBreak()] }),
      h1('1. Introduction'),
      b("Walk into any paediatric urology clinic and you'll find phimosis near the top of the referral list. It's also one of the conditions most frequently confused, over-treated, and under-investigated by non-specialist clinicians. The word itself - from the Greek phimoun, meaning 'to muzzle' - describes an inability to retract the penile prepuce over the glans. That's where the simplicity ends."),
      b("The term encompasses two clinically distinct entities. Physiologic phimosis is developmental - a normal state of the infant and young male in which natural adhesions and a narrow preputial ring prevent foreskin retraction. It is not a disease. It does not require treatment. It resolves on its own in the overwhelming majority of cases, following a predictable natural history documented in cohort studies spanning five decades. The foundational cohort of Oster (1968), in Danish schoolboys, demonstrated that only 1% of 17-year-olds had a non-retractile foreskin - down from nearly 100% at birth."),
      bc("Pathologic phimosis is something else entirely. It's an acquired condition in which inflammation, infection, or fibrotic scarring creates a fixed, non-compliant preputial ring that won't loosen with time. Balanitis xerotica obliterans (BXO) - the penile manifestation of lichen sclerosus (LS) - accounts for the majority of pathologic phimosis in circumcision specimens from both boys and adults, with histological confirmation rates of 40-80% in published surgical series. Untreated, BXO can extend to the glans and meatus, producing urethral stenosis, urinary obstruction, and a documented premalignant potential for squamous cell carcinoma.", [1, 2]),
      b("Despite these clear distinctions, clinical misclassification remains common. Parents of uncircumcised toddlers are told their child has phimosis and referred for circumcision when the foreskin is perfectly normal for age. Conversely, adult men with progressive scarring, dysuria, and white plaque-like preputial change cycle through primary care for months without diagnosis or referral. Both errors carry real consequences."),
      b("This review aims to clarify how to distinguish the two forms of phimosis, how to grade severity, how to evaluate the patient systematically, and how to match treatment to diagnosis. It draws on textbook urology, current guidelines, and the best available clinical trial and systematic review evidence."),

      // ── 2. ANATOMY ──
      h1('2. Relevant Anatomy and Normal Prepuce Development'),
      h2('2.1 Anatomy of the Prepuce'),
      b("The prepuce (foreskin) is a double-layered retractile fold of penile skin that covers and protects the glans penis. Its outer layer is continuous with the penile shaft skin; its inner layer is a mucosal epithelium rich in Meissner's corpuscles and other mechanoreceptors, contributing to erogenous sensitivity. The preputial ring - the most distal opening of the prepuce - is the anatomical point relevant to phimosis grading: it is here that narrowing or fibrosis produces non-retractility."),
      b("The frenulum connects the inner prepuce to the ventral glans at the 6 o'clock position. The preputial space between the inner prepuce and glans is occupied at birth by smegma and natural adhesions. These adhesions are not pathological; they represent an embryologically normal state in which separation of the glans from the inner prepuce has not yet been completed."),
      h2('2.2 Normal Development and Natural History of Physiologic Phimosis'),
      bc("At birth, physiologic phimosis is essentially universal. The preputial orifice is narrow and the foreskin is adherent to the glans in nearly all newborns. Over time, a combination of keratinisation of the inner preputial surface, smegma production, and intermittent erections breaks down these adhesions and progressively widens the preputial opening. This is a gradual, age-dependent process that does not require manual retraction or any external intervention to proceed.", [3, 4]),
      b("Population data consistently describe the following developmental trajectory: approximately 40-50% of boys have a fully retractile foreskin by age 5; rising to approximately 80% by age 10; and fewer than 1-2% of males have persistent true physiologic phimosis by puberty and early adulthood. Cohort data from Chinese schoolboys (n=10,421) and Taiwanese schoolboys (n=2,149) replicate the original Scandinavian findings and establish this natural history across diverse ethnic populations."),
      b("The practical implication is unambiguous: in a 3-year-old with a non-retractile foreskin and no symptoms, the correct management is parental reassurance and observation - not referral for circumcision. Forcible retraction of a physiologically non-retractile foreskin should be actively discouraged; it causes pain, micro-trauma, and can produce true cicatricial scarring where none previously existed - ironically creating pathologic phimosis from a normal developmental variant."),

      // ── 3. CLASSIFICATION ──
      h1('3. Classification and Staging'),
      h2('3.1 Physiologic vs. Pathologic: The Essential Distinction'),
      b("Distinguishing physiologic from pathologic phimosis is primarily a clinical examination finding, not a laboratory test or imaging result. The key differentiating features are:"),
      b("Physiologic phimosis: smooth, pliable, healthy-appearing preputial skin; no scarring, discolouration, or plaque formation; asymptomatic at rest; ballooning during micturition may occur but does not indicate urinary obstruction; expected to improve with advancing age; typically presents in children under 10 years."),
      bc("Pathologic phimosis: inelastic, thickened, or fibrotic preputial ring; white, pale, parchment-like, or lichenified discolouration (characteristic of BXO); changes may extend from the preputial ring to the glans or meatus; symptomatic - dysuria, bleeding, recurrent infection, painful erections; does not resolve spontaneously; can occur at any age but predominantly in post-pubertal males and adults.", [1, 5]),
      h2('3.2 Grading Systems'),
      b("Several clinical grading systems have been proposed to standardise assessment. The most widely referenced is the Kikiros grading scale (1993), ranging from Grade 0 (fully retractile prepuce with no tension) to Grade 5 (absolutely no retraction possible, pinhole meatus). The Beaugé classification provides an alternative framework based on the degree of foreskin retractility and associated symptoms."),
      b("For practical clinical use, a three-tier system is most actionable: Mild (Grade 1-2): partial retraction possible; Moderate (Grade 3): retraction to urethral meatus only; Severe/Pinhole (Grade 4-5): minimal or no retraction; meatus possibly obscured. Importantly, grade alone does not dictate treatment - the presence or absence of BXO and patient symptoms are equally critical determinants."),

      // ── 4. EPIDEMIOLOGY ──
      h1('4. Epidemiology'),
      bc("The prevalence of phimosis depends on age, definition, and the population studied. Using strict symptomatic criteria, pathologic phimosis occurs in approximately 1-3% of adult uncircumcised males. Population-based estimates of circumcision rates significantly influence reported prevalence, as phimosis is by definition absent in circumcised males.", [3]),
      b("BXO has a bimodal age distribution, with peaks in childhood (mean age at diagnosis approximately 8 years, range 1-16) and in adulthood (third to fifth decades). True incidence is difficult to establish due to inconsistent histological confirmation. Population-level estimates range from 0.07% to 0.9%, but histological BXO prevalence in phimosis surgical specimens consistently reaches 40-80% in published series - substantially exceeding pre-operative clinical diagnosis rates and indicating significant under-recognition in non-surgical settings."),
      bc("Penile lichen sclerosus (the umbrella term for BXO) is associated with autoimmune conditions - morphoea, vitiligo, thyroid disease, alopecia areata - in a subset of patients, suggesting an immunological pathogenesis. Genetic susceptibility, local trauma, chronic infection, and infectious triggers (HPV, Borrelia spirochaetes) have all been proposed but not definitively established.", [2]),
      b("Recognised risk factors for pathologic phimosis and BXO include: recurrent episodes of balanitis or balanoposthitis; diabetes mellitus (candidal and bacterial balanitis are substantially more common); chronic catheterisation; concomitant dermatological conditions including atopic eczema; and, critically, a history of forcible foreskin retraction in childhood."),

      // ── 5. CLINICAL EVALUATION ──
      h1('5. Clinical Evaluation'),
      h2('5.1 History'),
      b("A focused history should establish: the age of onset and duration of non-retractility; whether it is new (suggesting pathologic acquisition) or lifelong; the presence of symptoms including ballooning during voiding, dysuria, haematuria, pain, or discharge; episodes of recurrent balanoposthitis; sexual dysfunction or painful erections in adolescents and adults; any prior treatment attempts including forcible retraction; and, in adults, any dermatological history suggesting systemic lichen sclerosus or associated autoimmune disease."),
      b("Parents of young children often present with anxiety about a normal developmental finding, having received incorrect advice that the foreskin should retract by a specific age. Taking time to explain the natural history is itself a therapeutic intervention - and prevents both unnecessary parental anxiety and unnecessary surgical referrals."),
      h2('5.2 Physical Examination'),
      bc("Examination of the prepuce is straightforward and requires no instrumentation. The clinician assesses: the degree of retractility using the grading system described above; the appearance of the preputial skin (smooth and pliable versus thickened, white, scarred, or atrophic); the extent of involvement (limited to the preputial ring or extending to glans, meatus, or frenulum); meatal calibre; and evidence of active infection, excoriation, or fissuring.", [5]),
      b("Forcible retraction during examination should not be performed. A gentle assessment of skin quality at the preputial orifice is sufficient. The characteristic white ring or 'cigarette paper' crinkled appearance of BXO is often visible without full retraction and is diagnostically highly suggestive."),
      b("Urinary flow should be assessed in symptomatic patients. Clinically significant obstructive phimosis produces a narrow, deviated, or interrupted urinary stream, which parents or patients can usually describe accurately. Formal uroflowmetry should be considered if bladder or urethral involvement is suspected."),
      h2('5.3 Investigations'),
      b("Laboratory investigations and imaging are not routinely required. Targeted investigations include: urinalysis and culture (if UTI is suspected, particularly in febrile children or cases with recurrent infection); fasting blood glucose or HbA1c (in adults with recurrent candidal balanitis, to exclude diabetes mellitus); STI screening (gonorrhoea, chlamydia, herpes simplex) in sexually active adults with recurrent balanitis or discharge; and histopathology of all excised preputial or foreskin tissue - this is mandatory, not optional, as clinical examination consistently underestimates BXO prevalence and cannot exclude penile intraepithelial neoplasia (PeIN) or SCC."),

      // ── 6. NON-SURGICAL TREATMENT ──
      h1('6. Non-Surgical Treatment Options'),
      h2('6.1 Topical Corticosteroids'),
      bc("Topical corticosteroids are the established first-line pharmacological treatment for physiologic phimosis when intervention is indicated. The most extensively studied agents are betamethasone 0.05-0.1% cream or ointment and triamcinolone acetonide 0.1%, applied to the preputial ring twice daily for 4-8 weeks. Their mechanism includes softening of collagenous tissue at the preputial ring, local anti-inflammatory action, and facilitation of gradual atraumatic retraction.", [6, 7]),
      bc("A 2022 systematic review and meta-analysis by Lygas and Joshi evaluating pharmacotherapeutic options for adult phimosis identified limited but broadly consistent evidence supporting the safety of topical steroids, with heterogeneous but generally positive outcomes regarding symptom reduction and improvement in retractability. Methodological heterogeneity across included trials was significant, and the authors called for higher-quality research incorporating patient-reported outcome measures.", [6]),
      bc("In paediatric populations, the evidence base is more robust. A 2024 randomised double-blind trial (Nunes et al.) demonstrated an overall treatment success rate of approximately 70% with betamethasone 0.2% over 60 days in children aged 3-10 years. The trial also compared the addition of hyaluronidase to betamethasone (Group A: 75.4% success) versus betamethasone alone (Group B: 64.1% success), finding no statistically significant difference (p=0.18). Importantly, salivary cortisol measurements confirmed no systemic absorption in either group, establishing the safety of topical application.", [7]),
      b("A clinically critical observation in recent trial data is the association between preputial skin appearance and treatment outcome: success rates of 72% were observed in children with healthy-appearing skin at baseline, falling to 29% in those with altered skin appearance (p=0.007). This strongly reinforces the clinical principle that topical pharmacotherapy is substantially less likely to succeed when established fibrosis is already present - and that 'failed steroid therapy' in such a patient warrants BXO evaluation rather than a repeat prescription."),
      b("Practical prescribing: betamethasone 0.05% cream or ointment, applied to the preputial ring with gentle upward traction twice daily after washing. A 4-6 week course is standard; if no improvement is evident by 6-8 weeks, reassessment for BXO change and consideration of surgical referral is appropriate."),
      h2('6.2 Manual Stretching and Physical Dilation Devices'),
      bc("Manual stretching - graduated dilation of the preputial opening using fingers or a dilator after topical steroid softening - is a component of many conservative protocols. The Phimostop silicone tube system provides controlled, sustained gentle prepuce dilation without surgery and has shown favourable short-term outcomes in published case series, though long-term data remain limited.", [8]),
      b("Manual stretching without prior topical steroid preparation is likely to produce micro-tears and paradoxically worsen scarring. The evidence-based approach combines a steroid course first, with stretching initiated once tissue compliance is improved."),
      h2('6.3 Topical Calcineurin Inhibitors and Adjunct Agents'),
      b("Tacrolimus 0.1% and pimecrolimus 1%, topical calcineurin inhibitors used for steroid-sparing management in dermatology, have been explored in BXO and recurrent LS. Evidence is limited to small case series and one small trial. Some symptomatic benefit and anti-inflammatory effect have been reported, but remission rates are lower than with potent topical steroids and these agents are not currently considered standard of care. Ozonated olive oil has been reported as an adjunct post-circumcision in BXO management, with limited evidence of benefit in reducing meatal restenosis rates."),

      // ── 7. SURGICAL TREATMENT ──
      h1('7. Surgical Treatment Options'),
      h2('7.1 Circumcision'),
      bc("Circumcision - the surgical removal of the prepuce - is the definitive treatment for pathologic phimosis and constitutes the only absolute indication for the procedure in children. For BXO confined to the foreskin, circumcision is curative in approximately 90% of cases. The rate of BXO recurrence at the glans or meatus post-circumcision is lower when the procedure is performed early and all excised tissue is submitted for histological analysis.", [9]),
      b("Established techniques include: the forceps-guided method (haemostatic clamp compresses the foreskin before excision - widely used in adults); the dorsal slit technique (midline incision releases the constricting phimotic ring, used as a temporising measure or when immediate retractility is required); sleeve resection (freehand excision with two parallel circumferential incisions, providing precise control over skin removal); and device-based methods including the Plastibell and Gomco clamp (widely used in neonatal and paediatric settings for their standardisation and low complication rates)."),
      bc("A 2025 narrative review by Hasan et al. confirmed that circumcision, when performed by trained providers under appropriate anaesthesia with sterile technique, carries predominantly minor early complications with very low rates of severe adverse events. Reported complication rates include: haemorrhage 0.2-5% (most common), wound infection 1-2%, meatal stenosis, wound dehiscence, and, rarely, penile injury. Adult circumcision under local anaesthesia is a safe outpatient day-case procedure in experienced hands.", [9]),
      bc("Laser circumcision has been evaluated in comparative studies. A 2024 narrative review by Rosato et al. found laser approaches appeared to offer shorter operative time and potentially reduced postoperative complication rates compared with traditional circumcision, though the evidence base remains limited to case series and comparative cohort data, and device availability is not universal.", [8]),
      h2('7.2 Preputioplasty and Prepuce-Sparing Procedures'),
      bc("Preputioplasty - surgical widening of the preputial opening without removal of the prepuce - provides a foreskin-preserving option for patients with phimosis but without BXO-confirmed disease. The most commonly described technique is dorsal slit with transverse closure (applying the Heineke-Mikulicz principle to the preputial ring) or Y-V plasty. Published series report success rates of 70-90% with high patient satisfaction scores in selected patients.", [8]),
      b("The essential caveat is BXO. Preputioplasty is contraindicated in pathologic phimosis caused by BXO - retained BXO-affected foreskin tissue will continue to scar and re-stenose, leading to treatment failure and eventual requirement for circumcision anyway. BXO must be excluded not merely clinically but histologically before a prepuce-sparing approach is adopted."),
      b("Novel in-situ stapler devices that simultaneously crush, haemostase, and excise the prepuce in a single application have been evaluated in several trials and appear to reduce operative time while maintaining efficacy. A 2025 RCT by Yuan et al. assessed adjunctive triamcinolone acetonide combined with recombinant bovine basic fibroblast growth factor to prevent post-operative scar formation after stapler circumcision, with positive results supporting the combination approach."),
      h2('7.3 Meatotomy and Meatoplasty'),
      bc("Where BXO has extended to produce meatal stenosis, meatotomy (surgical enlargement of the meatal opening) or formal meatoplasty is required. Meatal stenosis complicates 20-40% of BXO cases and may persist or develop after circumcision. Endoscopic dilation provides temporary relief but is not definitive. Buccal mucosal graft urethroplasty is the preferred technique for established urethral BXO involvement and offers durable outcomes in specialist hands.", [2]),

      // ── 8. SPECIAL POPULATIONS ──
      h1('8. Special Populations and Clinical Considerations'),
      h2('8.1 Neonates and Infants'),
      b("Phimosis in the neonatal period is physiologic by definition. Neonatal circumcision - when performed - is for religious, cultural, or preventive reasons, not therapeutic ones. The AAP Task Force on Circumcision (2012) concluded that health benefits of neonatal male circumcision outweigh risks, warranting access, but stopped short of a universal recommendation. European paediatric urology bodies (EAU, BAPS, ESPU) do not recommend routine neonatal circumcision. Counselling families should explicitly clarify that a non-retractile foreskin in a newborn is expected and normal."),
      h2('8.2 Children: Avoiding Over-Treatment'),
      b("A substantial proportion of paediatric phimosis referrals represent physiologic phimosis in healthy boys whose families have received incorrect guidance. The correct response to a 3-year-old with a non-retractile, healthy-looking foreskin and no symptoms is reassurance, an explanation of normal development, advice against forcible retraction, and discharge. No medications. No surgery. No further review unless symptoms develop."),
      h2('8.3 Adolescents'),
      b("Physiologic phimosis persisting into puberty may become symptomatic as erections and sexual activity begin. Topical steroid therapy is first-line in adolescents with physiologic phimosis. BXO should be actively looked for; if present, circumcision counselling should begin. Adolescent patients benefit from confidential, age-appropriate discussion about their condition, the realistic outcomes of treatment, and the importance of follow-up."),
      h2('8.4 Adults'),
      bc("Adult-onset phimosis is almost invariably pathologic. A man who previously had a retractile foreskin and now presents with progressive tightening, dysuria, or white preputial change should be assumed to have BXO until histologically proven otherwise. Diabetes mellitus must be excluded. Topical steroid therapy can be trialled but success rates are substantially lower than in paediatric physiologic phimosis, particularly when fibrosis is established. Circumcision under local anaesthesia as a day-case is the appropriate and effective definitive treatment.", [6, 8]),
      h2('8.5 Diabetes Mellitus'),
      b("Diabetic men are substantially over-represented in adult phimosis referrals. Chronic candidal and bacterial balanoposthitis in poorly controlled diabetes generates progressive preputial scarring. Optimising glycaemic control is the essential first step - circumcision in uncontrolled diabetes carries higher wound complication rates. Once metabolic status is stabilised, circumcision frequently resolves the cycle of recurrent balanitis."),
      h2('8.6 Oncological Risk and Long-Term Surveillance'),
      bc("BXO carries a documented premalignant potential. SCC of the penis has been identified in BXO-associated tissue in retrospective series, with reported malignant transformation rates ranging from 0.3% to 9% across studies - a wide range reflecting heterogeneous follow-up periods and case definitions. All excised foreskin tissue from pathologic phimosis must be submitted for histopathology. Patients with confirmed BXO warrant long-term surveillance (typically annual review), patient education on self-examination, and a low threshold for rebiopsy of any new, changing, or suspicious lesions.", [1, 2]),

      // ── 9. PARAPHIMOSIS ──
      h1('9. Paraphimosis: A Related Urological Emergency'),
      b("Paraphimosis is distinct from phimosis and constitutes a urological emergency. It occurs when a partially retractile foreskin, once retracted behind the glans corona, cannot be returned to its natural position. A tight constricting ring of foreskin traps venous outflow; the glans and prepuce distal to the ring engorge progressively with oedema. Without prompt reduction, arterial occlusion and ischaemic necrosis of the glans can develop."),
      b("First-line management is manual reduction: sustained firm compression of the oedematous glans (with both thumbs, often after applying granulated sugar or ice to reduce oedema by osmosis) while simultaneously advancing the foreskin forward over the glans with the fingers. This succeeds in the majority of cases. If manual reduction fails, a dorsal slit under local anaesthesia immediately releases the constricting ring. Circumcision should follow electively after inflammation has fully subsided."),
      b("Paraphimosis is substantially preventable. Healthcare providers performing catheterisation, penile examination, or any procedure requiring foreskin retraction must always replace the foreskin to its natural position before completing the procedure. This should be a documented clinical checklist item in any setting where urethral catheterisation is routine."),

      // ── 10. ALGORITHM ──
      h1('10. Evidence-Based Treatment Algorithm'),
      b("The following stepwise approach integrates the evidence reviewed above into a practical clinical framework:"),
      b("Step 1 - Characterise the phimosis. Inspect the preputial skin: smooth and pliable (physiologic) or white, scarred, inelastic, atrophic (pathologic/BXO-suspicious)."),
      b("Step 2 - Age and symptom context. Physiologic phimosis in an asymptomatic child under 10: reassure, advise against forcible retraction, and discharge with written information. Physiologic phimosis with symptoms (recurrent UTI, functionally obstructive voiding, patient or parental distress): initiate topical betamethasone 0.05% twice daily for 6 weeks."),
      b("Step 3 - Review at 6-8 weeks. Successful response to steroid: continue if incomplete, reassess at 12 weeks. No response: reassess skin appearance for BXO change. If no BXO: consider repeat course or prepuce-sparing surgical referral. If BXO confirmed or suspected: refer for circumcision; all tissue to histopathology."),
      b("Step 4 - Pathologic phimosis / BXO at any age: surgical referral. Circumcision is the standard of care. Meatotomy or meatoplasty if meatal involvement is confirmed. Establish long-term BXO surveillance protocol."),
      b("Step 5 - Adult phimosis: exclude diabetes and STI; trial topical steroid if no established scarring; low threshold for circumcision if BXO present or conservative therapy fails within 8 weeks."),
      b("Step 6 - Paraphimosis: emergency manual reduction; dorsal slit if reduction fails; elective circumcision after resolution."),

      // ── TABLES ──
      new Paragraph({ children: [new PageBreak()] }),
      h1('Table 1. Physiologic vs. Pathologic Phimosis: Key Differentiating Features'),
      sp(),
      richTable(
        ['Feature', 'Physiologic Phimosis', 'Pathologic Phimosis (BXO)'],
        [
          ['Definition', 'Normal developmental non-retractility of the prepuce', 'Acquired non-retractility due to fibrotic scarring (BXO/LS)'],
          ['Age of presentation', 'Infancy to early childhood; resolves by adolescence in ~99%', 'Any age; peaks in childhood (mean 8 yrs) and adulthood'],
          ['Preputial skin appearance', 'Normal, smooth, soft, healthy colour', 'White, pale, parchment-like, atrophic, lichenified, or fissured'],
          ['Scarring / cicatrix', 'Absent', 'Present - characteristic white cicatricial preputial ring'],
          ['Natural history', 'Spontaneous resolution in ~99% by late adolescence', 'Does not resolve; progressively worsens without treatment'],
          ['Symptoms at rest', 'Usually none; ballooning during voiding is common but benign', 'Dysuria, bleeding, recurrent infection, painful erections'],
          ['Urinary obstruction', 'Not present (ballooning is not obstructive)', 'May occur with severe narrowing or meatal stenosis'],
          ['BXO / histology', 'Not applicable', 'BXO confirmed histologically in 40-80% of surgical specimens'],
          ['Malignant potential', 'None', 'Documented premalignant potential; SCC association (0.3-9%)'],
          ['First-line treatment', 'Reassurance; topical steroid only if symptomatic', 'Topical steroid (early/mild only); circumcision (definitive)'],
          ['Forcible retraction', 'Absolutely contraindicated - creates iatrogenic scarring', 'Contraindicated'],
          ['Histopathology of excised tissue', 'Not indicated (clinical diagnosis sufficient)', 'Mandatory - all excised tissue must be sent for histology']
        ]
      ),
      sp(),

      new Paragraph({ children: [new PageBreak()] }),
      h1('Table 2. Treatment Options for Phimosis: Evidence Summary'),
      sp(),
      richTable(
        ['Treatment', 'Indication', 'Agent / Technique', 'Reported Success Rate', 'Evidence Level', 'Key Limitations / Notes'],
        [
          ['Topical betamethasone 0.05-0.1%', 'Physiologic phimosis (first-line); early pathologic without BXO', 'BID application to preputial ring x 4-8 wks', '65-90% (paediatric); lower in adults with scarring', 'RCT / Systematic Review', 'Success strongly predicted by healthy skin appearance; no systemic absorption demonstrated [7]'],
          ['Topical triamcinolone 0.1%', 'Alternative or equivalent to betamethasone', 'BID x 4-8 wks', '60-85%', 'RCT [11]', 'Non-inferior to betamethasone in RCT; OTC hydrocortisone less potent'],
          ['Topical calcineurin inhibitors (tacrolimus / pimecrolimus)', 'BXO steroid-sparing; recurrent/refractory disease', 'BID topical application x 8-12 wks', 'Modest symptomatic benefit only', 'Small case series', 'Not standard of care; limited efficacy data; steroid-sparing role only'],
          ['Manual stretching + topical steroid combination', 'Moderate physiologic phimosis; prepuce-preservation preference', 'After steroid softening: progressive digital dilation', 'Additive to steroid alone', 'Observational', 'Do NOT use without prior steroid; micro-tears worsen scarring'],
          ['Phimostop silicone dilation tube', 'Conservative dilation; adult physiologic phimosis', 'Graduated silicone device; daily self-insertion', 'Favourable short-term series', 'Observational / case series [8]', 'Long-term data limited; requires patient compliance'],
          ['Preputioplasty (dorsal slit / Y-V plasty)', 'Physiologic phimosis; prepuce-preserving surgical option; no BXO', 'Widening of preputial ring; various freehand or plasty techniques', '70-90% in selected series', 'Retrospective case series', 'Absolutely contraindicated in BXO; tissue recurrence if BXO present; histopathology required'],
          ['Circumcision (standard surgical)', 'Pathologic phimosis / BXO; recurrent balanoposthitis; failed conservative therapy', 'Forceps-guided / sleeve resection / Plastibell / Gomco', 'Curative ~90% for foreskin-confined BXO', 'Multiple RCTs / Systematic Reviews / Guidelines [9]', 'Gold standard; all specimens require histopathology; meatal stenosis may require additional procedure'],
          ['Laser circumcision', 'Pathologic and symptomatic physiologic phimosis', 'CO2 / diode laser excision of prepuce', 'Shorter operative time; reduced early complications vs. conventional', 'Comparative cohort studies / Review [8]', 'Device availability limited; long-term outcomes equivalent to conventional'],
          ['Meatotomy / buccal mucosal meatoplasty', 'BXO with meatal stenosis post-circumcision', 'Endoscopic dilation (temporising) or buccal mucosal graft urethroplasty (definitive)', 'Buccal graft: durable outcomes; endoscopy: temporary', 'Case series [2]', 'Specialist procedure; reserved for BXO urethral involvement']
        ]
      ),
      sp(),

      new Paragraph({ children: [new PageBreak()] }),
      h1('Table 3. Phimosis Grading (Modified Kikiros Scale) and Recommended Management'),
      sp(),
      richTable(
        ['Grade', 'Description', 'Skin Appearance', 'Retractility', 'Recommended First-Line Management'],
        [
          ['Grade 0', 'Normal retractile foreskin - no phimosis', 'Normal, healthy, soft', 'Full retraction; glans fully exposed without tension', 'No treatment required; routine foreskin care advice'],
          ['Grade 1 - Mild', 'Near-complete retraction; tightens at coronal sulcus', 'Normal, pliable skin', 'Retraction almost complete; minimal ring tightening', 'Reassurance if asymptomatic; topical betamethasone if symptomatic'],
          ['Grade 2 - Moderate', 'Partial retraction; meatus visible', 'Usually normal; inspect for early ring change', 'Meatus visible; glans not fully exposed', 'Topical betamethasone 0.05% BID x 6-8 wks; review at 6 wks'],
          ['Grade 3 - Moderate-Severe', 'Partial retraction; meatus barely visible', 'Inspect for BXO - ring may show early pallor', 'Limited retraction; only urethral meatus visible', 'Topical steroid trial if no BXO; surgical referral if BXO present or steroid fails'],
          ['Grade 4 - Severe', 'Minimal retraction; only preputial opening visible', 'BXO changes probable if adult or acquired onset; white pallor', 'No meaningful retraction', 'Surgical referral; circumcision recommended; histopathology mandatory'],
          ['Grade 5 - Pinhole', 'No retraction; urine exits as narrow stream', 'BXO highly probable; white fibrotic ring; fissuring common', 'Absolutely non-retractile', 'Urgent surgical referral; circumcision; meatotomy if meatal stenosis; urgent urology if urinary retention']
        ]
      ),
      sp(),

      // ── DISCUSSION ──
      h1('11. Discussion'),
      b("The fundamental message of this review is as important as it is frequently ignored in clinical practice: phimosis is not a single diagnosis. The term describes a physical finding - a non-retractile foreskin - but that finding carries completely different clinical implications depending on whether the skin is normal and developing or scarred and fibrotic."),
      b("The most consequential clinical error isn't mismanaging established pathologic phimosis - it's over-treating physiologic phimosis in children. Circumcision rates for phimosis in paediatric populations remain far higher than the actual incidence of pathologic disease can justify. A 2025 survey of Latin American paediatric surgeons and urologists found that 80% recommended circumcision at age 4-5 regardless of symptoms, and only 30% routinely offered corticosteroids as first-line therapy. In Chile, phimosis is the leading cause of paediatric surgical waiting list entries - a striking demonstration of the downstream clinical and resource costs of diagnostic misclassification at the point of first contact."),
      bc("Topical corticosteroid therapy for physiologic phimosis is backed by robust evidence, demonstrable safety (no systemic absorption in RCT-level data), and success rates of 65-90% in appropriately selected patients. There is no justification for bypassing it. The critical clinical insight from recent trial evidence is the role of skin appearance as a treatment response predictor: healthy preputial skin responds to steroids; altered, scarred, or fibrotic skin does not. When topical steroid therapy 'fails,' the correct response is a reassessment of the diagnosis - specifically, an active search for BXO change - not an automatic surgical referral for circumcision. If BXO is found, circumcision is appropriate and should be performed promptly. If BXO is absent, preputioplasty or a repeat steroid course is reasonable.", [6, 7]),
      bc("BXO remains under-recognised in non-specialist settings. The gap between its histological prevalence in circumcision specimens (40-80%) and its pre-operative clinical diagnosis rate reflects the limitations of clinical assessment alone and the tendency of non-specialists to label any non-retractile foreskin as simple phimosis. The oncological implications - a documented association with penile SCC, albeit with wide confidence in transformation rate estimates - make this under-recognition clinically important, not just academically interesting. All excised preputial tissue must go to histopathology, without exception.", [1, 2]),
      b("On the innovation front, device-based circumcision, laser-assisted techniques, and foreskin-preserving preputioplasty continue to mature. The evidence for laser circumcision suggests genuine advantages in operative efficiency. Preputioplasty remains an excellent option for the right patient: physiologic phimosis, no BXO, foreskin-preserving preference, and an experienced surgeon. But patient selection is not negotiable. A preputioplasty performed in a patient with unrecognised BXO will fail, and the patient will eventually require circumcision anyway - having already undergone one unnecessary procedure."),

      // ── CONCLUSION ──
      h1('12. Conclusion'),
      bc("Phimosis management comes down to making the right diagnosis first. Most boys with a non-retractile foreskin do not need treatment - they need time, and their parents need honest reassurance. When intervention is required for physiologic phimosis, topical betamethasone works in the majority of cases and should precede any surgical consideration. Pathologic phimosis and BXO require a fundamentally different approach: careful examination for fibrotic changes, active referral for circumcision, mandatory histopathological analysis of all excised tissue, and structured long-term follow-up for recurrence and malignant change.", [1, 2, 6, 9]),
      b("As neonatal circumcision rates continue to fall in Western countries and primary care providers encounter phimosis with increasing frequency, the ability to distinguish physiologic from pathologic phimosis at the first clinical contact determines every subsequent management decision. This review provides the clinical framework, grading tools, and evidence base to do exactly that."),

      // ── DECLARATIONS ──
      h1('Declarations'),
      b('Conflicts of interest: The author declares no conflicts of interest.'),
      b('Funding: This narrative review received no external funding.'),
      b('Ethics statement: Not applicable (narrative review; no primary patient data collected).'),

      // ── REFERENCES ──
      new Paragraph({ children: [new PageBreak()] }),
      h1('References'),
      rf(1,  'Charlton OA, Smith SD. Balanitis xerotica obliterans: a review of diagnosis and management. Int J Dermatol. 2019;58(7):777-785. doi:10.1111/ijd.14236. PMID: 30315576'),
      rf(2,  'Nguyen ATM, Holland AJA. Balanitis xerotica obliterans: an update for clinicians. Eur J Pediatr. 2020;179(1):9-16. doi:10.1007/s00431-019-03516-3. PMID: 31760506'),
      rf(3,  'Leeson C, Vigil H, Witherspoon L. Foreskin care: Hygiene, importance of counselling, and management of common complications. Can Fam Physician. 2025;71(2):97-105. doi:10.46747/cfp.710297. PMID: 39965976'),
      rf(4,  'Oster J. Further fate of the foreskin: incidence of preputial adhesions, phimosis, and smegma among Danish schoolboys. Arch Dis Child. 1968;43(228):200-203.'),
      rf(5,  'Rosato E, Miano R, Germani S, Asimakopoulos AD. Phimosis in Adults: Narrative Review of the New Available Devices and the Standard Treatments. Clin Pract. 2024;14(1):361-376. doi:10.3390/clinpract14010028. PMID: 38391414'),
      rf(6,  'Lygas A, Joshi HB. An evaluation of the pharmacotherapeutic options for the treatment of adult phimosis: a systematic review of the evidence. Expert Opin Pharmacother. 2022;23(9):1065-1073. doi:10.1080/14656566.2022.2075697. PMID: 35536559'),
      rf(7,  'Nunes E Santos RMS, Figueiredo AA, de Bessa Junior J, et al. Does the addition of hyaluronidase to betamethasone in topical treatment of phimosis improve results? A randomized double-blind clinical trial. J Pediatr Urol. 2024;20(5):839-845. doi:10.1016/j.jpurol.2024.06.039. PMID: 39079875'),
      rf(8,  'Rosato E, Miano R, Germani S, Asimakopoulos AD. Phimosis in Adults: narrative review of new devices and standard treatments. Clin Pract. 2024;14(1):361-376. PMID: 38391414'),
      rf(9,  'Hasan MR, Hossain A, Sakib N. Male Circumcision Revisited: A Narrative Review of Techniques, Therapeutic Indications, and Preventive Benefits. Cureus. 2025;17(12):e98581. doi:10.7759/cureus.98581. PMID: 41357715'),
      rf(10, 'Folaranmi SE, Corbett HJ, Losty PD. Does application of topical steroids for lichen sclerosus (BXO) affect circumcision rate? A systematic review. J Pediatr Surg. 2018;53(11):2224-2227. PMID: 29395150'),
      rf(11, 'Chamberlin JD, Dorgalli C, Abdelhalim A, et al. Randomized open-label trial comparing topical triamcinolone to hydrocortisone for treatment of phimosis. J Pediatr Urol. 2019;15(4):396.e1-396.e5. PMID: 31130504'),
      rf(12, 'Kwok R, Shah TT, Minhas S. Recent advances in understanding and managing Lichen Sclerosus. F1000Res. 2020;9:F1000 Faculty Rev-272. PMID: 32518626'),
      rf(13, 'Smith and Tanagho\'s General Urology, 19th Edition. McGraw-Hill Education; 2020. Chapter: Specific Disorders of the Urethra and Penis. pp.664-667.'),
      rf(14, 'Bailey and Love\'s Short Practice of Surgery, 28th Edition. CRC Press; 2022. Chapter 85: Disorders of the Penis and Scrotum. pp.9839-9858.'),
      rf(15, 'Campbell-Walsh-Wein Urology, 12th Edition. Elsevier; 2021. Chapter 44: Paediatric Genital Disorders. pp.1116-1120.')
    ]
  }]
});

Packer.toBuffer(doc).then(buf => {
  fs.writeFileSync('/tmp/workspace/phimosis-review/Phimosis_Narrative_Review.docx', buf);
  console.log('SUCCESS');
}).catch(e => { console.error(e); process.exit(1); });